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Type 2 diabetes mellitus is often associated with obesity and hypertension, with insulin 
resistance as a hallmark of the prevailing disease. Angiotensin II (Ang-II) is involved in 
the pathogenesis of insulin resistance by exerting negative modulation on insulin signal 
transduction.  
 
In the current study, we explored the roles of Des-aspartate-angiotensin I (DAA-1) and 
angiotensin IV (Ang-IV) in the signalling cascades of Ang-II and insulin in diet-induced 
diabetes. Six to eight-week old male C57BL/6J mice were fed a high-fat-high-sucrose 
(HFD) or control diet for 52 weeks. The HFD mice were treated with DAA-1 (600 
nmole/ kg/ day), Ang-IV (400 nmole/ kg/ day) or drinking water by gavage, starting from 
week 0 or week 24 of the diet regime. Body weight, blood glucose and blood insulin were 
measured periodically. Orally-administered DAA-1 and Ang-IV had no effect on body 
weight and both fasted insulin level but exerted significant hypoglycemic action. 
 
At the end of 52 week, the skeletal muscles of HFD animals treated with DAA-1 were 
found to have (i) decreased levels of ROS, gp91 of NADPH oxidase, pJNK and pIRS-1307 
(ii) improved insulin-stimulated pTyr-IR, pTyr-IRS-1, PI3K activation, pAkt and GLUT4 
and (iii) reduced level of AT1-JAK-2-IRS-1 complex. Losartan and indomethacin were 
shown to abolish DAA-1 induced hypoglycemic effect. These findings suggest that 




On the other hand, the skeletal muscles of HFD animals treated with Ang-IV were found 
to have similar decreased levels of ROS, gp91 of NADPH oxidase, pJNK, pIRS-1307 and 
AT1-JAK-2-IRS-1 complex, but to a lesser extent compared to the DAA-1 treated 
animals. Interestingly, the skeletal muscles of Ang-IV treated animals showed significant 
increased levels of insulin-stimulated pAkt and GLUT4 translocation in the absence of 
improvement in pTyr-IR, pTyr-IRS-1 and PI3K attachment to IRS-1. These findings 
suggest that Ang-IV attenuates the insulin signalling via an alternative pathway. This 
postulation is supported by the observation that the skeletal muscles of Ang-IV treated 
animals were found to have high levels of pTyr-IRAP and PI3K attachment to IRAP. 
Divilinal-Ang-IV was shown to abolish Ang-IV induced hypoglycaemic effect. 
Collectively, the data suggest that Ang-IV exerts its hypoglycaemic action through AT4 
receptor. 
 
Lastly, the effects of the angiotensin peptides on hyperglycaemic-induced pancreatic 
beta-cell death were investigated. It was demonstrated that DAA-1, but not Ang-IV 
attenuated hyperglycaemic-induced beta cell death in a dose dependent manner. In 
addition, losartan was found to inhibit the actions of DAA-1. This finding suggests that 
DAA-1 exerts its protective effect via AT1 receptors in hyperglycaemic-induced cell 
death. 
 
Taken together, DAA-1 and Ang-IV are potential prophylactic and acute oral anti-
diabetic agents that exert hypoglycemic action through AT1 and AT4 receptors 
respectively. The study also demonstrates for the first time the protective action of DAA-
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1 against beta cell death under in vitro hyperglycaemic conditions. In addition to the 
enhancement of our understanding to the pathogenesis of diet-induced diabetes, the 







Diabetes mellitus is a medical disorder characterised by the failure of the body to clear 
blood glucose, either by not responding to the actions of insulin or not secreting enough 
insulin, and sometimes both. Insulin is a hormone secreted in the pancreas responsible for 
regulating the circulatory glucose level and cellular glucose uptake. There are two major 
types of diabetes, namely, type 1 and type 2. Other types of diabetes include gestational 
diabetes and several forms of monogenic diabetes. At advanced stages, diabetes can lead 
to complications like cardiovascular disease, chronic renal failure, retinal damage and 
gangrene (Korec 2002; Kramer, et al. 2003; Schlingemann, et al. 1999).  
 
Type 1 diabetes mellitus (T1DM) known as insulin dependent diabetes mellitus, is 
characterised by beta cell failure to secrete insulin deficiency. T1DM is often caused by 
autoimmune attack of T cells on beta cells (Rother 2007). T1DM patients are treated with 
insulin, often respond well and maintain normoglycemia.  
 
In contrast, T2DM patients show impaired glucose tolerance and are not able to clear 
blood glucose efficiently after insulin bolus (Bjornholm and Zierath 2005). The 
inefficiency in clearing blood glucose is termed insulin resistance. In the earliest stage of 
the disease, both the insulin-induced glucose uptake in skeletal muscle and the 
suppression of hepatic glucose production are decreased. The pancreatic beta cells 
compensate the lack up glucose uptake by increasing insulin secretion in order to 
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maintain euglycemia. As hyperinsulinemia continues, insulin resistance exacerbates to 
impaired glucose tolerance, leading to beta cell failure and eventually, overt diabetes 
(Kahn 1994; Li, et al. 2004; Stumvoll, et al.). Currently, there are several oral 
medications available to achieve glycemic control in T2DM patients that aim to increase 
insulin secretion or responsiveness.  Sulfonylureas and meglitinides are used to increase 
insulin release from the pancreas while biguanides and thiazolidinediones to increase 
insulin responsiveness at muscle level (Hermann, et al. 1994; Inzucchi, et al. 1998).  In 
addition, alpha-glucosidase inhibitor was used to modify intestinal carbohydrate 
absorption and lipase inhibitor to modify the absorption of fat (Grunberger, et al. 2007; 
Horio and Ohtsuru 2001). However, persistent hyperglycemia would lead to gradual 
destruction of pancreatic beta cells (Li et al. 2004) and insulin injection in combination 
with several oral hypoglycemic agents is required as a long-term therapy (Turner, et al. 
1999). Although diet intervention, weight reduction and regular exercise are proven to be 
the best methods to improve glucose metabolism, compliances to these interventions are 
usually not sustained (Schneider, et al. 1992; Uusitupa, et al. 1993). 
 
The prevalence of diabetes is increasing in an alarming rate. In 2000, the World Health 
Organisation had declared the disease a worldwide epidemic and the number of people 
suffering from diabetes is predicted to rise from 171 million in 2000 to 366 million in 
2030 (Wild, et al. 2004), affecting more than 5.2 percent of the world’s population. 
T2DM is reported to be the most common type of diabetes in developed countries. In the 
United States of America alone, there were 24 million people diagnosed with T2DM in 
2008 and another 57 million people are estimated to have pre-diabetes (Centers for 
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Disease Control and Prevention 2007). The observation could be the outcome of the 
growing trends in urbanisation, sedentary lifestyle and western dietary pattern in these 




Figure 1.1 The postulated disease progression of diabetes in developed countries. 
The growing trends in urbanisation, sedentary lifestyle and western dietary pattern in 
developed nations have exposed man to higher risk of developing obesity. Alterations in 
free fatty acids (FFA) metabolism play important roles in the pathogenesis of the insulin 
resistance in obesity. In the earliest stages of the disease, both the insulin-induced glucose 
uptake in skeletal muscle and the suppression of hepatic glucose production are decreased. 
The pancreatic beta cells compensate the lack up glucose uptake by increasing insulin 
secretion in order to maintain euglycemia. As hyperinsulinemia continues, insulin 
resistance exacerbates to impaired glucose tolerance, leading to beta cell failure and 




The main pathogenesis of T2DM is insulin resistance but the primary defect and its 
mechanism is complex. However, both the “thrifty genotype” and “carnivore-connection” 
hypotheses suggested that the disorder is caused by a combination of genetic and 
environment factors (Kahn 1994). A geneticist, James V. Neel in 1962, first proposed the 
thrifty gene hypothesis. He explained that the thrifty genes that predispose to diabetes 
were an adaptation to cycles of feast and famine. These genes enabled the ancient hunter-
gathers to efficiently deposit fat during food abundance and increase survival during food 
scarcity. The thrifty genes that allowed humans to get fat rapidly were thus historically 
advantageous and hence naturally selected for into the human’s gene pool. In modern 
world, the constant surplus of energy resulted in the sudden rise in diabetes and obesity 
related diseases because the cycle of feast and famine was discontinued, particularly in 
the developed countries where western dietary and sedentary lifestyle prevails. The 
genetic predisposition to develop diabetes and obesity in human, once beneficial, is now 
deemed as a genetic disorder in the course of evolution.  
 
The metabolic defects, which precede the onset of T2DM, have been identified and seem 
to be genetically determined. In the first world countries, indigenous populations have 
higher T2DM prevalence rate than their non-indigenous counterparts. For example, the 
incidence of T2DM in Pima Indians has increased in an exponential rate in the past 
century compared to the non-native Americans (King and Rewers 1993). While in the 
Oceania, Australian Aborigines has four times higher prevalence of T2DM to that of the 
non-indigenous Australians (Schraer, et al. 1988). Interestingly, populations of European 
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ancestry worldwide are found to have a low predisposition to T2DM (Dowse and Zimmet 
1993). Miller and Colagiuri postulated a carnivore-connection theory to explain the high 
prevalence of T2DM in non-Europeans. In prehistoric times, our pre-human ancestors 
lived in a tropical climate and gathered fruits and berries. They consumed a high-
carbohydrate diet and evolved to utilise glucose as a source of energy and developed 
insulin sensitivity. But two million years of Ice Ages forced our ancestors to become 
carnivorous and adopted a low-carbohydrate, high-protein diet. Such diet required high 
degree of insulin resistance to retain glucose homeostasis, as indicated in several human 
and experimental animal studies. As a result, the natural selection pressure for insulin 
resistance gene was intensified and high frequency prevailed in human evolution. Only as 
recent as 10,000 years ago, our planet became warm. While the rest of the world’s 
population continued to experience high selection pressure for insulin resistance, the 
Europeans adopted agriculture and began to incorporate large amount of starch into their 
diet, leading to the relaxation of the selection pressure for insulin resistance (Eaton and 
Konner 1985). Over time, the prevalence of insulin resistance genes was lower in 
European population than any other populations as agriculture spread throughout 
Americas and Asia gradually. The world in seventeenth century saw the industrial 
revolution and drastic alterations in food manufacturing. In this era, man invented 
remarkable machines to increase food yield and animal domestication that transformed 
the quantity and quality of dietary carbohydrate. The starch produced by cereal milling is 
more digestible and entails higher postprandial glycaemic and insulin responses (Brand, 
et al. 1985; Heaton, et al. 1988). Unprecedentedly, modern high glycaemic index western 
diet requires beta cells to secrete large amounts of insulin ad infinitum (Jenkins, et al. 
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1988). Europeans experienced reduced selection pressure for insulin resistance as they 
were the first to adopt high-carbohydrate diet. Hence the prevalence of insulin resistance 
genes is lower in the European population, while recent epidemic of diet-induced 
diabetes is observed in the non-European populations (Lillioja, et al. 1991; Thorburn, et 
al. 1987).  
 
In addition to refined grains, the modern diet includes high intake of red meat. Although 
a good source for iron and protein, red meat has high saturated fat content and is 
recognised as a major contributing factor to various health diseases. Regular consumption 
of red meat has been linked to increase risks in cancer, cardiovascular diseases and 
T2DM (Fraser 1999; Giovannucci, et al. 1993; Song, et al. 2004; van Dam, et al. 2002). 
As a major health concern, the Food and Agriculture Organisation of the United Nations 
(FAO) announced that the meat consumption is expected to rise from 184 million metric 
tons in 1993 to 303 million metric tons in 2020 (Speedy 2003). A western diet is usually 
characterised by high carbohydrate and high fat intake (Halton, et al. 2006).  
 
Western diet has been shown to be the underlying cause for obesity, hyperlipidemia, 
hyperglycemia, hyperinsulinemia and reduced insulin sensitivity (DeFronzo and 
Ferrannini 1991). Growing trends in western dietary pattern and sedentary lifestyle in 
modern society have exposed man to higher risk of developing diet-induced T2DM. The 
Trust for America’s Health reported that two-third of American adults are obese and the 
rate of adult obesity had doubled from 15 percent in 1980 to 32 percent in 2004 with 
more than $120 billion spent yearly on obesity-related treatments (Ridgeway, et al. 2004). 
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In this respect, intensive research on the pathogenesis of diet induced diabetes and other 
obesity related cardiovascular diseases were conducted using obese animal models. 
Increase in plasma free fatty acid (FFA) concentration is a characteristic of high fat diet 
and play a major role in both diet-induced T2DM and cardiovascular disease (Paolisso, et 
al. 1995b). Alterations in FFA metabolism play an important role in the pathogenesis of 
the insulin resistance. It is suggested that elevations in plasma FFA concentration inhibits 
insulin-induced glucose transport and subsequently reduces the rates of glucose oxidation 
and muscle glycogen synthesis (Boden and Shulman 2002). This reduction in insulin- 
induced glucose uptake leads to the development of T2DM patients (Boden and Chen 
1995).  
 
In animal studies, obese rodents have increased plasma tumor necrosis factor alpha 
(TNF#) level, FFA level, cellular Jun N-terminal kinase 1 (JNK-1) activity and insulin 
receptor substrate 1 (IRS-1) serine phosphorylation, which were in turn shown to inhibit 
insulin-stimulated translocation of glucose transporter 4 (GLUT4) from cytosolic vesicles 
to plasma membrane, leading to decrease insulin sensitivity and glucose intolerance 
(Hirosumi, et al. 2002; Hotamisligil, et al. 1993; Paolisso et al. 1995b). Taken together, 
diet-induced obesity seems to negatively modulate insulin’s action by asserting numerous 





Insulin regulates the uptake of glucose in skeletal muscles and adipose tissues via a 
cascade of intracellular signalling. Insulin initiates its action by binding to the insulin 
receptor, which is a tyrosine kinase receptor (Rosen 1986) composed of heterotetrameric 
membrane glycoprotein consisting of 2 alpha subunits and 2 beta subunits (Kasuga, et al. 
1983). Insulin binds to the extracellular alpha subunit of the receptor and leads to a rapid 
autophosphorylation at multiple tyrosine residues of the intracellular domain ($ subunit) 
of insulin receptor. This creates a recognition motif for the phosphotyrosine-binding 
(PTB) domain of the IRS-1 (White and Yenush 1998). The activated IRS-1 initiates the 
GRB2 signalling pathway, which eventually through the ERK/ MAPK cascade promotes 
glycogen synthesis and cell growth. In addition, IRS-1 is also the major effector of 
insulin receptor action and tyrosine phosphorylated IRS-1 generates docking sites for 
phosphatidylinositol 3-kinase (PI3K) (Esposito, et al. 2001). This kinase contains a SH2 
regulatory and a SH3 catalytic subunit. The regulatory subunit binds to the activated IRS-
1 while the catalytic subunit phosphorylates membrane phosphatidylinositol 3,4-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3). The PIP3 then acts 
as a lipid second messenger to mediate the downstream events, which involve protein 
dependent kinase (PDK), phosphoinositide kinase B (Akt) and Protein kinase C. 
Activation of these kinases initiates a downstream signalling cascade leading to the 
translocation of glucose transporter 4 (GLUT4) from the intracellular vesicular store into 
the plasma membrane (White and Yenush 1998). On the cell surface, the GLUT4 
proteins transport glucose into the cell but facilitated diffusion (Wallberg-Henriksson, et 
al. 1988). The glucose is then utilised for energy production. As a negative feedback, 
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protein kinase C induces serine phosphorylation of insulin receptor and IRS-1, which 





Figure 1.2 Insulin signalling system in skeletal muscle. Insulin initiates its action 
through binding to the insulin receptor which creates a recognition motif for the PTB 
domain of the IRS-1. The activated IRS-1 initiates the GRB2 signalling pathway, which 
eventually through the ERK/ MAPK cascade promotes glycogen synthesis and cell 
growth. In addition, IRS-1 also generates docking sites for PI3K. The regulatory subunit 
of PI3K binds to the activated IRS-1 while the catalytic subunit phosphorylates 
membrane PIP2 to PIP3. The PIP3 will then act as a lipid second messenger to the 
downstream events which involve PDK, Akt and Protein kinase C. The activation of 
these kinases will initiate a downstream signalling cascade leading to the translocation of 
GLUT4 from the intracellular vesicular store into plasma membrane. On the cell surface, 
the GLUT4 proteins will transport glucose into the cell but facilitated diffusion. The 
glucose is then utilised for energy production. As a negative feedback, protein kinase C 




IRS-1 plays a pivotal role in insulin signalling. In its N-terminus, contains the Pleckstrin 
homology (PH) and PTB domains. PTB domain binds specifically to phosphorylated 
Tyr960 of the insulin receptor (White and Yenush 1998). The signalling substrate 
contains many tyrosine and serine/theornine phosphorylation sites. Numerous studies 
have demonstrated that modifications to the phosphorylation states of these sites 
regulated the function of IRS-1. When activated, the phosphorylation of Tyr608, Tyr628 
and Tyr658 in IRS-1 generates docking sites for SH2 containing PI3K, which is capable 
of transducing information for GLUT4 translocation (White and Yenush 1998). While 
phosphorylation of Tyr895 and Tyr1172/1222 provide binding motifs for the growth 
factor receptor-bound protein 2 (Grb2) and src homology 2 domain containing tyrosine 
phosphatase (SHP2) respectively (White 2003). Both Grb2 and SHP2 are responsible for 
activating the MAPK cascade, leading to glycogen synthesis and JNK activation (Pelicci, 
et al. 1992). By contrast, in the negative feedback, serine phosphorylation of IRS-1 at 
amino acids residue position 302, 307 and 312 induces a conformational change in the 
PTB domain of the substrate that reduces its binding affinity for the insulin receptor and 
PI3K, thereby minimising its activation (Aguirre, et al. 2002; Liu, et al. 2004) (Figure 
1.3). In the normal physiology, the balance between the positive tyrosine phosphorylation 
and negative serine phosphorylation of IRS-1 is maintained. Reduced IRS-1 tyrosine 
phosphorylation and PI3K activity are tightly linked to the decrease in glucose uptake in 
T2DM. Studies have found that factors mediating insulin resistance, like TNF#, FFA, 
cellular stress, Ang-II and hyperinsulinemia activate serine/threonine kinases that 
phosphorylate IRS-1, thus attenuate its signal transduction (Andreozzi, et al. 2004; 
Bloch-Damti, et al. 2006; Draznin 2006; Gao, et al. 2004). Insulin resistance in T2DM is 
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a pathological state in which the body fails to respond properly to normal levels of 
circulating insulin. Animals fed with western diet were shown to exhibit obesity, 
hyperglycemia and hyperinsulinemia (Fex, et al. 2007; Surwit, et al. 1988; West, et al. 
1992). These physiological conditions induce high levels insulin resistance mediating 
factors (Esposito, et al. 2006; Fex et al. 2007; Giugliano, et al. 2006; Wei, et al. 2006). 
Consequently, insulin-stimulated translocation of GLUT4 from cytosolic vesicles to 
plasma membrane is impaired, leading to the development of insulin resistance and 




Figure 1.3 The differential of effects on structure and function of IRS-1 by amino 
acid phosphorylation at various sites. In its N-terminus, IRS-1 contains the PH and 
PTB domains. PTB domain binds specifically to phosphorylated Tyr960 of the insulin 
receptor. The signalling substrate contains many tyrosine and serine/theornine 
phosphorylation sites. When activated, the phosphorylation of Tyr608, Tyr628 and 
Tyr658 in IRS-1 generates docking sites for SH2 containing PI3K, which is capable of 
transducing information for GLUT4 translocation. Phosphorylation of Tyr895 and 
Tyr1172/1222 provide binding motifs for Grb2 and SHP2, respectively. Both Grb2 and 
SHP2 are responsible for activating the MAPK cascade, leading to glycogen synthesis 
and JNK activation. In the negative feedback, serine phosphorylation of IRS-1 at amino 
acids residue position 302, 307 and 312 induces a conformational change in the PTB 






Figure 1.4 The effects of insulin resistance mediating factors in the skeletal muscle. 
Reduced IRS-1 tyrosine phosphorylation and PI3K activity are tightly linked to the 
decrease in glucose uptake in T2DM. TNF#, FFA, cellular stress, Ang-II and 
hyperinsulinemia activate serine/threonine kinases that phosphorylate IRS-1, thus 
attenuate its signal transduction. Physiological conditions like obesity, hyperglycemia 
and hyperinsulemia induce high levels insulin resistance mediating factors. Consequently, 
insulin-stimulated translocation of GLUT4 from cytosolic vesicles to plasma membrane 






The renin-angiotensin-system (RAS) is a hormone system that regulates blood pressure, 
sodium and water balance (Peach 1977; Reid, et al. 1978). Angiotensinogen is a 
tetradecapeptide synthesised mainly by the liver. Renin converts angiotensinogen to 
angiotensin (Ang) I (Genest, et al. 1983). Both angiotensinogen and Ang-I are 
biologically inactive. Angiotensin-converting enzyme (ACE) is responsible for the 
conversion of Ang-I to Ang-II by cleaving the C-terminal histidine-leucine from Ang-I 
(Johnston 1990). Aminopeptidase A and prolylendopeptidase further break down Ang-II 
to shorter fragments Ang-(1-7) and Ang-III respectively. Ang-(1-7) is formed via 
caboxypeptidase P cleavage of the phenylalanine residue of Ang-II (Ferrario, et al. 1997; 
Ferrario, et al. 2005). In a separate pathway, Ang-I is degraded to nonapeptide des-
aspartate-angiotensin-1 (DAA-1) by aminopeptidase X, single amino acid cleavage at the 
N-terminus (Sim and Radhakrishnan 1994; Sim and Qiu 1994). Ang-III can be formed 
followed by the actions of ACE at the C-terminus of DAA-1 (Figure 1.5). Further 
degradation of Ang-III by aminopeptidase B gives rise to form Ang-IV (Blair-West, et al. 
1971). Both Ang-III and Ang-IV are biologically active and Ang-IV can be further 
reduced to smaller fragments by endopeptidases like aminopeptidase N, 
dipeptidylaminopeptidase and caboxypeptidaes N (Unger, et al. 1988). Ang (4-8) and 
Ang (5-8) are major fragments degraded from Ang-IV. Recently, Ang (3-4), also a 
metabolite of Ang-IV, is found to be a potent ACE inhibitor and shown to possess 
antihypertensive effect in both animal and human by lowering the levels of Ang-II 
(Vercruysse, et al. 2008). In addition to circulating angiotensins of hepatic origin, there 
are also tissue-generated angiotensins found in brain, heart, kidney, pancreas and vascular 
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tissues with localised RAS (Campbell 1987; Celio and Inagami 1981; Dostal 2000; 
Leung, et al. 1998; Phillips, et al. 1993).  
 
Angiotensin receptors are transmembrane receptors that are coupled to intracellular G 
protein or tyrosine kinase for signal transduction (de Gasparo, et al. 2000). Classified into 
AT1 (AT1A and AT1B), AT2, AT3, AT1-7 and AT4, the receptors are distributed in the 
blood vessels, adrenal cortex, liver, brain and skeletal muscle with the exception of AT3 
receptors, that have been reported only in neuroblastoma (Dina and Jafari 2000; Thomas 
and Mendelsohn 2003). The physiological properties of the angiotensin peptides are 
determined by the location and the specificity of the membrane receptors (Martínez-




Figure 1.5 The renin-angiotensin system and its regulating peptidases. 
Angiotensinogen is synthesised mainly in the liver. Renin converts angiotensinogen to 
Ang-I. Both angiotensinogen and Ang-I are biologically inactive. ACE is responsible for 
the conversion of Ang-I to Ang-II by cleaving the C-terminal histidine-leucine from Ang-
I. Aminopeptidase A and prolylendopeptidase further break down Ang-II to shorter 
fragments Ang-(1-7) and Ang-III respectively. Ang-(1-7) is formed via caboxypeptidase 
P cleavage of the phenylalanine residue of Ang-II. In a separate pathway, Ang-I is 
degraded to nonapeptide DAA-1 by aminopeptidase X, single amino acid cleavage at the 
N-terminus. Ang-III can be formed followed by the actions of ACE at the C-terminus of 
DAA-1. Further degradation of Ang-III by aminopeptidase B gives rise to form Ang-IV. 






Circulatory Ang-II is the major bioactive peptide of the RAS that is responsible for 
vasoconstriction and exert multiple physiological effects on cardiovascular, renal and 
adrenal systems (Peach 1977; Reid et al. 1978). Ang-II acts through the G-protein 
coupled AT1 receptor (Chiu, et al. 1991a). Upon activation, phospholipase C, inositol 
1,4,5-triphosphoate and diacyglycerol transduce the action of calcium influx that is 
responsible for hypertensive and trophic actions of Ang-II (Chiu, et al. 1991b). Ang-III 
possesses similar biological activity to Ang-II albeit lesser binding affinity to AT1 




Ang-(1-7) has been shown to exert counterregulatory effects on the pressor and trophic 
actions of Ang-II through AT1-7 receptor, which is also known as the Mas receptor. As 
opposed to Ang-II, Ang-(1-7) actions include vasodilation and antihypertension and act 
as mediator to maintain the basal vascular tone through the release of prostaglandins and 
nitric oxide at the peripheral level (Hilchey and Bell-Quilley 1995). More importantly, 
Ang-(1-7) has been shown to positively modulate insulin-stimulated IRS-1 and Akt 
phosphorylation in rat heart in vivo (Giani, et al. 2007). 
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DAA-1 is an endogenous nanopeptide derived from an alternative degradation of Ang I 
(Sim, et al. 1994; Sim and Qiu 1994). DAA-1 was first described as a pharmacological 
agent in the 1970s and later discovered to be easily broken down by ACE(Sim et al. 
1994). Over the last two decades, Sim and his colleagues uncovered that DAA-1, in many 
ways, induces opposing responses of Ang-II. In spontaneously hypertensive rats, DAA-1 
was found to antagonise the pressor action to Ang-II and Ang-III in a dose-dependent 
manner and the anti-hypertensive and anti-hypertrophic effect were not inhibited by 
PD123319, an AT2 receptor antagonist (Sim and Min 1998; Sim and Qiu 1994). Further 
functional studies also revealed that Ang-II-induced incorporation of phenylalanine and 
thymidine (markers for hypertrophy and hyperplasia, respectively) were concentration-
dependently inhibited by DAA-1 through AT1 receptor in cardiomyocytes (Min, et al. 
2000). The cardioprotective action of DAA-1 through the binding to AT1 was confirmed 
in a binding assay in rat cardiac ventricles. DAA-1 also relieves pathologies in which 
Ang-II is associated, e.g. in attenuation of neotima formation in balloon catheter-injured 
rat carotid artery and age-related vascular hypertrophy (Sim et al 2004). It is well-
established that during myocardial ischemia, the renin-angiotensin system is activated 
(Noda et al 1993). The responses from enhanced Ang-II release cause or aggravate 
ischemia-reperfusion injury i.e. pressor effect, inflammation, remodelling and thrombosis 
(Dzau 2001). These effects are mediated by the activity of phospholipase C, inositol 
triphosphate and diacyglycerol following the activation of AT1 receptor. Alternatively, 
DAA-1 acts on the AT1 receptors that are coupled to the prostaglandin-dependent 
pathway, instead of the conventional inositol-triphosphate generating AT1 receptor. 
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When administered after treatment with DAA-1, indomethacin (101 mol/ kg) was shown 
to inhibit the attenuation of the infarct size of the ischemic reperfused rat heart, indicating 
that prostaglandins may be involved in transducing the attenuation (Wen, et al. 2004).  
 
Recently, DAA-1 was found to exert hypoglycemic action in a dose dependent manner in 
genetically pre-disposed diabetic GK rats and KKAy mice by increasing insulin-
stimulated IRS-1 tyrosine phosphorylation and GLUT4 translocation (Sim, et al. 2007). 
In the same study, it was found that DAA-1 has no effect on the plasma insulin level, 
suggesting that it exerts the action by attenuating insulin resistance. Although the exact 
pathways coupling DAA-1 to GLUT4 transportation is not yet known, it is likely that 
DAA-1 induces responses that counteract the pathological actions of Ang-II which cross-
talk with the insulin signalling pathway. The hypoglycaemic action of DAA-1 may be 
prostaglandin-dependent as one of the downstream actions of prostaglandins includes 
improvement of insulin sensitivity by the activation of peroxisome proliferator-activated 




There are numerous reports that suggest Ang-IV produces certain biological functions in 
the central nervous system. Ang-IV was first discovered to promote learning and memory 
by inducing the release of acetylcholine so as to enhance long-term potentiation in rat 
hippocampus (Lee, et al. 2001). Similarly, Ang-IV is shown to increase extracellular 
dopamine concentration in the rat striatum when administrated locally (Stragier, et al. 
2004). Despite the focus on the primary role of Ang-IV in learning and memory, the 
 25 
endogenous peptide is also shown to exert physiological effects in central and peripheral 
systems. Ang-IV dose-dependently increases blood pressure in anaesthetized rats after 
central administration. Like Ang-II and Ang-III, the hypertensive effect is AT1 receptor 
dependent (Averill and Diz 2000; Faure, et al. 2006; Phillips and Sumners 1998). Ang-IV 
is shown to be a full agonist to AT1 receptor, the EC50 value of the peptide to receptor is 
in the micromolar range (Capponi and Catt 1979; Le, et al. 2002). 
 
The response and specificity of Ang-IV is highly debated, especially its control of kidney 
blood flow. In the micromolar range, vascular injection of Ang-IV causes renal 
vasoconstriction leading to reduction in renal blood flow.  The observed decrease was 
mediated by the AT1 receptor (Handa 2006; Li, et al. 2006). Contradictorily, in 
nanomolar concentrations, the peptide is able to elicit physiological responses that are 
independent of AT1 receptors. As opposed to the AT1-mediated vasoconstriction, Ang-IV 
is able to increase renal cortical blood flow after vascular injection; the effect is not 
blocked by DuP 753, a specific AT1 receptor antagonist (Coleman, et al. 1998; Hamilton, 
et al. 2001). Ang-IV was also showed to increase intercellular adhesion molecule-1, 
interleukin 6, TNF# and activation of nuclear transcription factor-%B in vascular smooth 
muscle cells, suggesting its multiple roles in inflammatory diseases and immune 
responses (Esteban, et al. 2005; Kerins, et al. 1995). Although the mechanism by which 
the peptide elicits these effects remains unclear, the involvement of AT1 receptor is 
excluded as these responses were observed in AT1 receptor knock-out animals (Esteban 
et al 2005).  
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AT4 receptor is distinctively different from AT1 and AT2 receptors, in terms of structure 
and pharmacological properties. The receptor does not belong to the family of G-protein 
coupled receptor and instead is recognised to be a complex made up of several peptides, 
one of which, a 165 kDa peptide identified as insulin-regulated aminopeptidase (IRAP) 
(Bernier, et al. 1998; Zhang, et al. 1999; Zhang, et al. 1998). Also known as placental 
leucine aminopeptidase (PLAP), IRAP is a zinc-containing metalloprotein which has 
catalytic action of degrading hormones such as oxytocin, vasopressin, angiotensin III, 
Met-enkephalin and dynorphin via N-terminal amino acid cleavage (Albiston, et al. 2001; 
Rogi, et al. 1996). Ang-IV has high binding affinity to AT4 receptor; in particular, the 
first three amino acid residues of the peptide are shown to be critical for the peptide-
receptor interaction based on structure-activity studies (Sardinia, et al.). The exact 
molecular mechanism for the physiological effects induced by Ang-IV-IRAP interaction 
is yet not conclusive to date. However, the physiological actions of Ang-IV could be 
mediated by IRAP in three possible ways. 
 
1. Inhibition hypothesis 
Among the IRAP’s substrates, neuropeptides vasopressin and oxytocin are known to 
facilitate memory consolidation and improves reference memory respectively (de Wied, 
et al. 1993; Engelmann, et al. 1996). Recently, it was shown that in the presence of IRAP, 
N-terminal degradation of intravenously injected vasopressin and oxytocin is increased. 
This observation is further supported in increased circulatory endogenous vasopressin 
observed in IRAP knock-out animals (Wallis, et al. 2007). The memory-enhancing 
properties of Ang-IV could be the consequence of inhibiting the catalytic activity of 
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IRAP, leading to the build-up of its substrates. Indeed, several in vitro studies have 
shown that Ang-IV and its analogues are inhibitors of the aminopeptidase activity of 
IRAP. These IRAP ligands (Norleucine-Ang-IV, LVV-haemorphin-7, divalinal-Ang-IV 
and Ang-IV) were shown to competitively inhibit the enzyme activity of IRAP within the 
range of nanomolar concentrations (Lee, et al. 2003; Lew, et al. 2003).  
 
2. Interference hypothesis 
As its name implies, IRAP is functionally responsive to insulin signalling and identified 
to be intracellular vesicles that co-localises with glucose transporter GLUT4 (Czech and 
Corvera 1999; Keller, et al. 1995). In adipocytes, cardiomyocytes and skeletal muscle 
cells, it was well described that IRAP co-translocates with GLUT4 to the cells surface in 
response to insulin stimulation (Martin, et al. 1997; Ross, et al. 1996; Sumitani, et al. 
1997). The GLUT4/ IRAP recycling model is currently under intensive investigation but 
remains to be understood. At the cell surface, the catalytic domain of IRAP is 
extracellular and the amino terminus is cytoplasmic. While in the GLUT4 vesicles, the 
amino-terminal domain is exposed to the cytoplasm and the catalytic domain concealed 
within the lumen (Handa 2001). The cytoplasmic tail of IRAP contains the dileucine 
sequence in position 76 and 77, which is particularly important for subcellular 
localisation. Next to the dileucine motif, contains several tyrosine and serine 
phosphorylation sites; particularly, Ser80 (Johnson, et al. 2001). An in vitro study 
revealed that protein kinase C-zeta, activated by insulin stimulation, phosphorylated 
IRAP at Ser80 and Ser90 (Handa 2001). Although not verified with in vivo studies yet, it 
is highly possible that the insulin-stimulated serine phosphorylation close to the dileucine 
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motif of IRAP, may be crucial for the translocation of IRAP to the cell surface. In 
addition, the cytoplasmic tail contains the acyl-coenzyme A dehydrogenases (ACDs) 
binding sites in position 55-82. It was well-described in both adipocytes and skeletal 
muscle that ACD inhibitors disrupted the ACD activation and its binding to the dileucine 
motif of IRAP (Chi and Lodish 2000; Yeh, et al. 2007). The disruption was observed in 
concert with the translocation of GLUT4 to the cell surface. Figure 1.6 illustrates the 
hypothetical IRAP/GLUT4 recycling model. The binding of Ang-IV to IRAP may 
therefore interfere with its recycling and leads to prolonged exposure of GLUT4 at the 
cell surface. Increased glucose uptake was shown to facilitate memory and enhance 
cognitive function. The attenuation in IRAP recycling could be the basis behind the 





Figure 1.6 The hypothetical IRAP/ GLUT4 recycling model. IRAP is functionally 
responsive to insulin signalling and identified to be intracellular vesicles that co-localises 
with glucose transporter GLUT4. IRAP co-translocates with GLUT4 to the cells surface 
in response to insulin stimulation. At the cell surface, the catalytic domain of IRAP is 
extracellular and the amino terminus is cytoplasmic. While in the GLUT4 vesicles, the 
amino-terminal domain is exposed to the cytoplasm and the catalytic domain concealed 
within the lumen. Upon insulin stimulation, protein kinase C-zeta is activated and 
phosphorylates IRAP at Ser80 and Ser90, which are close to the dileucine motif of IRAP.  
The phosphorylation may be crucial for the translocation of IRAP to the cell surface by 
displacing the binding of ACDs, in position 55-82. The disruption of ACD-IRAP binding 
is observed in concert with the translocation of GLUT4 to the cell surface. 
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Intracellular signalling hypothesis 
 
There are several evidences to show that binding of Ang-IV to IRAP transduces 
intracellular signalling. In the rat striatum, local administration of Ang-IV and its 
analogue, LVV-H7, induced dramatic increase in dopamine release (Stragier, et al. 2007). 
The effect was not attenuated by co-administrations of aminopeptidase inhibitor, AT1 and 
AT2 receptor antagonists (Stragier et al. 2004). Ang IV was also shown to induce i) 
transient intracellular [Ca2+] increase, ii) phosphorylation of several kinases, iii) 
activation of cell proliferation signalling molecules like PI3K, Erk-1/2 and Akt (Chen, et 
al. 2001; Handa 2001; Handa, et al. 1999; Li, et al. 2002; Lu, et al. 2005). One of the 
common characteristics for the membrane proteins like IRAP in the M1 metallopeptidase 
family is to form homodimers (Shipp and Look 1993). Upon dimerisation, the receptor 
can transduce its signals similar to growth factor receptors (Gaetaniello, et al. 1998; 
Mittrücker, et al. 1995). For example, structurally related dipeptidylpeptidase IV was 
found to form transmembrane homodimers and mediated tyrosine phosphorylation of 
several signalling messengers and activation of MAP kinases in T lymphocytes upon 
antibody stimulation (Gaetaniello et al. 1998; Hegen, et al. 1993; Kähne, et al. 2000).  
 
It is clear that IRAP can behave either as an enzyme or receptor depending upon tissue 
type and Ang-IV could mediate its biological effects via a mixture of distinctively 
different mechanisms. In particular, Ang-IV influences on IRAP/GLUT4 recycling and 
intracellular signalling provide potential therapeutic strategies for the treatment of 





In recent years, Ang-II is found to be involved in the pathogenesis of diet-induced 
diabetes and related cardiovascular diseases. Ang-II was shown not only to modulate 
blood pressure, but also weight gain and insulin resistance in diet-induced obese animals 
(Dobrian, et al. 2000; Farah, et al. 2007; Kouyama, et al. 2005). The downstream 
effectors of angiotensin AT1 receptor cross talk with the pathway of GLUT4 translocation 
through the attenuation of IRS-1 tyrosine phosphorylation and PI3K activation is a major 
part of this modulation. The involvement by which Ang-II inhibits insulin signalling is 
intensively investigated. Ang-II was shown to induce the activation of JNK-1 to stimulate 
serine phosphorylation of several components of the insulin signalling pathway, in 
particular, IRS-1 (Folli, et al. 1997). Serine phosphorylated IRS-1 induces poor 
interaction with the insulin receptor, leading to decreased insulin signal transduction and 
consequently, negatively modulates GLUT4 translocation. Ang-II is capable of 
stimulating rapid tyrosine phosphorylation of Janus kinase 2 (JAK-2), which induces its 
tyrosine phosphorylation and association with IRS-1 (Eguchi, et al. 1998; Ishida, et al. 
1995). The resulting concomitant binding of PI3K to the IRS-1 forms a large inactive 
complex with AT1 receptor. Several in vivo studies have shown that the docking of IRS-1 
to AT1 receptor stimulates its tyrosine phosphorylation and PI3K recruitment but inhibits 
its enzymatic activity (Carvalheira, et al. 2003; de Carvalho-Filho, et al. 2007; Saad, et al. 
1995). Furthermore, activation of AT1 receptor by Ang-II is shown to stimulate NADPH 
oxidase, leading to the generation of ROS and induces inhibition of insulin signalling in 
skeletal muscle cells (Wei et al. 2006). The negative impacts of Ang-II signal 
transduction on insulin signalling are illustrated in Figure 1.4. The impairment could be 
 32 
reverted by blocking Ang-II actions with ACE inhibitors and angiotensin receptor 
blockers (ARBs). ACE inhibitors and ARBs treatments were found to provide cardiac 
and renal protection (Gronholm, et al. 2005; Higueruelo, et al. 1998), as well as improve 
glucose intolerance in diabetic animals (Shiuchi, et al. 2002; Wang, et al. 2003). In major 
clinical trials, patients with heart diseases who received ACE inhibitors and ARBs 
treatments were found to have significant reduced risk of T2DM (Barnett, et al. 2004; 
Brenner, et al. 2001; Lewis, et al. 2001). These clinical findings support the role of Ang-
II as a mediator in obesity related diseases and blocking the actions of Ang-II have 
therapeutic benefits. The summary of evidences is presented in Table 1.1.  
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 Author Year Experiments Outcomes Conclusions 
Dietary Studies 
10775577 Dorian 2000 Developed increased 
aorta wall and renin 
activity 
Diet induced obesity 
develops hypertension 
and RAS activation 
17166491 Mundy 2006 Modulated vascular 
activity in response to 
ANG II and expression 
of its receptors 
High dietary fat intake 
increases 
cardiovascular risk by 
modifying response to 
Ang II 





Animals fed high 
fat diet 
Emax increased Hypertension in high 
fat diet is associated 
with increase reactivity 
to 5-HT and Ang II 
Knock-out Studies 
15878965 Kouyama 2005 Knockout AT1a in 
C57 mice fed with 
high fat diet 
Reduced weight gain 
and insulin resistance 
Ang II modulates diet-
induced weight gain 
and energy expenditure 
via AT1  
15793237 Yvan-Charvet 2005 AT2 deletion in 
C57 mice fed with 
high fat diet 
Decreased weight gain 
and glucose intolerance 
Ang II modulates 
glucose intolerance 
through AT2 
14747283 Ma 2004 Knockout 
plasminogen 
activator inhibitor 1 
in C57 mice fed 
with high fat diet 
Decreased weight gain, 
hyperglycemia, and 
hyperinsulinemia 
Ang II activated 
plasminogen activator 
inhibitor 1 induces 
insulin resistance and 
weight gain  
Pharmacological Inhibition Studies 
16137672 Gronholm 2005 Omapatrilat on 
diabetic GK rats 
Reduced cardiac weight ACE inhibition has 
cardioprotective effect 
in diabetes 
9751601 Higueruelo 1998 Fosinopril on obese 
Zucker rats 
Reduced eicosanoid 
secretion, serum lipid, 
urinary protein excretion 
and glomerular lesions 
ACE inhibition has 
renal protective effect 
in diabetes 








sensitivity and glucose 
uptake in diabetes 
15037562 Shiuchi 2003 Valsartan on 
diabetic KKAy 
mice 
Increased insulin by 
induced GLUT4 
translocation and 




sensitivity and glucose 
uptake in diabetes 
15774768 Boustany 2005 Losartan on SD rats 
with high fat diet 
Decreased systolic blood 
pressure 
AT1 antagonism 
reverses blood pressure 
in diet-induced obesity 
16717145 Araki 2006 Telmisartan on C57 
mice fed with high 
fat diet 
Decreased levels of 
adiponectin, resistin and 
uncoupling protein 1 
AT1 antagonism 
prevents development 
of diet-induced obesity 
and metabolic 
disorders  
















The main aims in the treatment of T2DM are to maintain normoglycemia, minimise 
cardiovascular risk factors and avoid drugs that can aggravate blood insulin and lipid 
abnormalities. Diet, weight management and exercise have been shown to improve 
glycemic control.  
 
Diet modification can improve several aspect of T2DM. Caloric restriction through 
dietary manipulation is shown to be a significant factor in improvement in glycemic 
control and insulin sensitivity (Henry, et al. 1985). In addition, weight loss is associated 
with reduced insulin resistance and increased insulin secretion in T2DM obese patients 
(Wing, et al. 1994). Regular exercise, independent of weight loss is also beneficial in 
T2DM, which leads to increased insulin responsiveness and delay the progression of 
impaired glucose tolerance (Schneider et al. 1992). Although diet, weight reduction and 
regular exercise can improve glucose metabolism, patients’ compliance to intensive 
dietary and exercise programme is often not sustainable (Henry et al. 1985; Niskanen, et 
al. 1990; Norris, et al. 2004).   
 
Lifestyle intervention has its limitation in maintaining glycemic goals, and most of the 
T2DM patients will require medication over the course of their disease. There are several 
medications available for glycemic control. As summarised in Table 1.2, these drugs acts 
through different mechanism of action to (i) increase insulin release, (ii) increase insulin 
responsiveness and (iii) modify intestinal absorption of carbohydrate. In addition, insulin 
injection is also often used as a pharmacological treatment.  
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Sulfonylureas are the earliest class of oral hypoglycaemic drugs and there are numerous 
derivatives available at present (Bressler and Johnson 1997). The first generation of 
sulfonylureas used therapeutically were tolbutamide and chlorpropamide. Sulfonylureas 
are insulin secretagogue and act by blocking KATP channels on the cell membrane of 
pancreatic beta cells, leading to increased intracellular calcium that consequently, 
increased fusion of insulin granule to cell membrane and increased secretion of insulin 
(Aguilar-Bryan, et al. 1995). The side effects of sulfonylureas are usually well tolerated, 
except prolonged and severe hypoglycaemia (Holstein, et al. ; Tessier, et al. 1994). 
However, it is a major concern in obese T2DM patients that this class of drug stimulate 
appetite and often cause weight gain. Newer and more potent sulfonylureas include 
glipizide and glimepiride (Jönsson, et al. 1994; Rydberg, et al. 1994). Recently developed 
meglitinides (repaglinide and nateglinide) have identical mechanism of action but lack 
sulfonylurea moiety (Fuhlendorff, et al. 1998).  
 
Biguanides belong to a class of oral anti-hyperglycaemia drugs that increase skeletal 
muscle glucose uptake and utilisation. In addition, biguanides reduce hepatic glucose 
production, as a result, reduce blood glucose level (Bailey 1992). Metformin is the only 
drug of this class available as both phenformin and buformin are withdrawn from the 
market due to high risk of lactic acidosis (Gan, et al. 1992; Stang, et al. 1999). Although 
the mechanism of action is not fully understood, metformin is widely used in obese 
T2DM patients as it has additional benefit of reducing blood level of low density 
lipoproteins (Wu, et al. 1990).  
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Thiazolidinediones is a class of drugs that induces hypoglycaemic effect by binding to 
nuclear peroxisome proliferator-activated receptors gamma (PPAR"), transcripts several 
specific genes that are responsible in improving insulin sensitivity and glucose and lipid 
metabolism (Vidal-Puig, et al. 1997). The therapeutic onset of thiazolidinediones is slow 
as the hypoglycaemic effect is achieved after one to two months of treatment and weight 
gain is usually observed (Lebovitz, et al. 2001; Phillips, et al. 2001). However, high 
incidence of fatal hepatotoxicity has been reported in the first drug in this class and in 
March 2002, troglitazone was removed from the market (Watkins and Whitcomb 1998). 
Although liver injury is very rare in patients treated with currently marketed 
thiazolidinediones (rosiglitazone and pioglitazone), recent studies have shown there may 
be an increased risk of coronary heart disease with rosiglitazone (Nesto, et al. 2003). 
Therefore, thiazolidinediones are generally reserved as a second-line treatment to 
synergise hypoglycaemic effect in combination to other anti-diabetic drugs.  
 
Alpha-glucosidase inhibitors decrease the rate of digestion of dietary carbohydrates 
(oligosaccharides and disaccharides) to glucose by acting on the enzyme in the small 
intestines (Meneilly, et al. 2000). This class of drug is less potent compared to 
sulfonylureas and biguanides, and the main side effects include flatulence and diarrhoea 
(Holman, et al. 1999). Due to reduced efficacy and poor tolerance, alpha-glucosidase 
inhibitors are often prescribed as an additive anti-diabetic medication. 
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Other anti-diabetic drugs include Glucagon-like protein (GLP) agonist and amylin 
analogue. These drugs aim to suppress postprandial glucagon release. Exenatide is the 
first GLP agonist drug approved for the treatment of T2DM (Egan, et al. 2002). It acts by 
binding to membrane GLP receptor, stimulating the release of insulin from pancreas (Xu, 
et al. 1999). However, GLP agonist causes gastrointestinal discomfort and hemorrhagic 
pancreatitis (DeFronzo, et al. 2005). In contrast, amylin analogue does not stimulate 
insulin secretion; it lowers blood glucose level by glucagon suppression (Kong, et al. 
1998). Pramlintide, administered subcutaneously, is the only amylin analogue available 
clinically and adverse effects include hypoglycaemia and nausea (Hollander, et al. 2003; 
Ratner, et al. 2002).   
 
Insulin therapy is used when patients developed late diabetes and experience persistent 
hyperglycaemia despite use of oral hypoglycaemic drugs and lifestyle modifications 
(UKPDS1995a; 1995b).  
 
In present time, diet-induced obesity is the common cause of two highly prevalent and 
overlapping maladies- T2DM and cardiovascular diseases (Natali and Ferrannini 2004; 
Reaven, et al. 2004). The Hypertension in Diabetes Study conducted in United Kingdom 
revealed that hypertension is common in newly diagnosed T2DM and is associated with 
obesity (HDS1993). The hypertensive T2DM patients have increased risk for 
cardiovascular morbidity and mortality. Insulin resistance is found to play a pivotal role 
in the development of obesity, T2DM, hypertension and metabolic syndrome. Of late, 
several studies have revealed the existence multi-level molecular cross-talk between 
 38 
insulin and Ang-II signalling systems (Calegari, et al. 2005; Carvalheira et al. 2003; de 
Carvalho-Filho et al. 2007; Golovchenko, et al. 2000) This tight connection between the 
signal transduction pathways plays a pathogenic role in the association of obesity, 
diabetes and cardiovascular diseases. Therefore, monotherapy using conventional anti-
diabetic agent may be inadequate in treating obese T2DM patients with cardiovascular 
diseases.  
 
As discussed, Ang-II signal transduction has negative impact on insulin signalling. The 
impairment could be reverted by blocking Ang-II actions with ACE inhibitors and ARBs. 
Patients with heart diseases who received ACE inhibitors and ARBs treatments were 
found to have significant reduced risk of T2DM in major clinical trials (Jauch, et al. 1987; 
Kurtz and Pravenec 2004; Moan, et al. 1994) Drugs that target the actions of Ang-II are 
hence potential therapeutics for T2DM and its associated medical conditions.   
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On the basis that (i) diet induced diabetes is becoming a worldwide epidemic (ii) Ang-II 
is a mediator in obesity-related diseases (iii) current treatments using ACE inhibitors and 
ARBs that involve blocking the upstream actions of Ang-II are not effective anti-diabetic 
agents (iv) DAA-1 antagonizes the deleterious actions of Ang II (v) DAA-1 attenuates 
hyperglycemia and insulin resistance in type 2 diabetic GK rats and KKAy mice (vi) 
Ang-IV found to be an active metabolite of DAA-1 and (vii) Ang-IV binds to IRAP and 
has potential roles in GLUT4 trafficking. DAA-1 was demonstrated to dose-dependently 
exerts hypoglycemic action in genetically pre-deposited diabetic animals by upregulation 
of insulin-stimulated IRS-1 tyrosine phosphorylation and GLUT4 translocation (Sim et al. 
2007) and Ang-IV, was also found to exert hypoglycemic effects on diabetic animals 
(unpublished findings). 
 
The aims of the study are to (i) determine the evidence of insulin resistance in the HFD 
mouse model and treatment with these peptides improved this resistance (ii) investigate 
the signalling mechanisms of insulin resistance and action in this model by molecular 
studies and concurrent treatment with angiotensin receptor and prostaglandin blockers (iii) 
investigate the potential therapeutic effects of the angiotensin peptides on pancreatic beta 
cells under in vitro hyperglycaemic condition.  
 
Briefly, 6 to 8 weeks old male C57 BL/ 6J mice were randomly divided and fed with 
either standard diet or high fat high sucrose diet (HFD). Animals fed HFD group was 
divided into 2 groups treated orally administered with either DAA-1 or Ang-IV. 
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Treatments of the peptides began either on the 0th week or the 24th week of HFD 
introduction. The study lasted 52 weeks, in which we recorded body weight (4 weekly up 
to 52 weeks), food consumption (4 weekly up to 48 weeks), blood glucose (4 weekly up 
to 48 weeks), insulin (at 48 weeks) and free fatty acid (at 24 & 48 weeks) levels. At the 
end of the study, the animals were sacrificed and the hindlimb skeletal muscles extracted 
for further analysis of GLUT4 translocation, reactive oxygen species formation and AT1 
receptor and IRAP activation. In addition, the effects of AT1 receptor blocker, losartan 
and IRAP inhibitor, divilinal Ang-IV on DAA-1 and Ang-IV hypoglycaemic action were 
also studied. Lastly, an in vitro study was also conducted to measure the effects of DAA-
1 and Ang-IV on pancreatic beta-TC-6 cells in hyperglycaemic condition. A general 
overview of the study protocol is outlined in Figure 1.7.  
 
These findings will enhance our understanding on the (i) establish a diet-induced diabetes 
animal model (ii) determine the hypoglycemic actions of DAA-1 and angiotensin IV in 






Figure 1.7 Outline of the experimental strategy. Six to 8 weeks old male C57 BL/ 6J 
mice were randomly divided and fed with either standard diet or high fat high sucrose 
diet (HFD). The animals from the HFD group were orally administered with either DAA-
1 or Ang-IV. Treatments of the peptides began either on the 0th week or the 24th week of 
HFD introduction. In a 52-week study, the body weight (4 weekly up to 52 weeks), 
energy of food consumed (4 weekly up to 48 weeks), blood glucose (4 weekly up to 48 
weeks), blood insulin level (at 48 weeks) and blood free fatty acid (at 24 & 48 weeks) of 
the test animals were measured. The animals were then sacrificed and the hindlimb 
skeletal muscles extracted for the study of GLUT4 translocation pathways, reactive 
oxygen species formation and AT1 receptor and IRAP activation. In addition, the effects 
of AT1 receptor blocker, losartan and IRAP inhibitor, divilinal Ang-IV on DAA-1 and 
Ang-IV hypoglycaemic action were also studied. Lastly, an in vitro study was also 










Five- to 6-week-old male C57BL/ 6J male mice were purchased from the National 
University of Singapore Centre for Animals Resources. The animals were housed in 
temperature controlled room at 25 ± 1 °C with lighting from 0700 – 1900 h daily and 
were allowed one week of acclimatisation period before the start of the study. The use of 
animals in this study was approved by Institutional Animal Care and Use Committee of 




The animals received either normal diet (ND, Specialty Feeds, Australia) or high-fat 
high-sucrose diet (HFD, Specialty Feeds, Australia) and water ad libitum. The ND 
consisted of 19% protein, 12% carbohydrates and 4.6% fat (total 13.5 kJ/ g), whereas the 
HFD consisted of 19% protein, 42% carbohydrates and 23% fat (total 20 kJ/ g). The 
composition of the diets is given in Table 2.1. 
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Table 2.1 Diet composition of normal diet and high-fat high-sucrose diet. 
 
  ND HFD 
Calculated caloric values 
 
Protein (%) 19 19.4 
Total Fat (%) 4.6 23 
Crude Fiber (%) 4.8 1.9 
Carbohydrates (%) 71.6 55.7 
Digestible Energy (kJ/ g) 13.5 20 
 
Ingredients (g/ kg) 
 
Wheat, Lupis, Barley, Soya meal and 
Fishmeal 
200 - 
Casein - 200 
D L-Methionine 3 3 
Sucrose 120 424 
Wheat Starch 434 50 
Cholesterol - 1.9 
Hydrogenated coconut oil + lecithin - 131 
Cocoa Butter - 50 
Canola oil 70 50 
Cellulose 50 50 
Calcium carbonate 13.1 13.1 
Sodium chloride 2.6 2.6 
Potassium sulfate 1.6 1.6 
Minerals 1.4 1.4 
Choline chloride 2.5 2.5 






The calculation of the energy consumed was based on the weight of the food pellet 
consumed by the animals for a 24-h period. The value was multiplied by the amount of 
digestible energy given in Table 3 (table of diet composition) divided by the weight of 
the animals. Measurement was taken every 4 weeks. The energy consumed was 




Animals were randomly divided into ND and HFD groups. HFD animals were orally 
administered DAA-1 (600 nmole/ kg/ day) or Ang-IV (400 nmole/ kg/ day) starting from 
0th week of the diet regime with drinking water as the vehicle. These doses were chosen 
as they were shown to exert maximum hypoglycemic effect in diabetic animals in 
previous study (Sim et al. 2007). In order to study the effects of angiotensin peptides after 
the onset of diet-induced diabetes, two additional groups of HFD animals were 
identically treated with DAA-1 and Ang-IV starting from the 24th week. Control animals 
from the respective diets were similarly treated with 0.1 ml of water by oral gavage. After 
52 weeks of treatment, the animals were then subjected to acute insulin stimulation (40 
U/ kg or 0.5 U/ kg) and sacrificed for various molecular studies. Each treatment group 









Group 1 ND control - mice fed with normal diet plus oral administration 
of drinking water/ day. 
 
Group 2 HFD control - mice fed with high-fat-high-sucrose diet plus oral 
administration of drinking water/ day. 
 
Group 3 HFD + DAA-1 (0) - mice fed with high-fat-high-sucrose diet plus oral 
administration of 600 nmole/ kg/ day DAA-1 
starting from 0th week of the diet regime. 
 
Group 4 HFD + Ang-IV (0) - mice fed with high-fat-high-sucrose diet plus oral 
administration of 400 nmole/ kg/ day Ang-IV 
starting from 0th week of the diet regime. 
 
Group 5 HFD + DAA-1 (24)- mice fed with high-fat-high-sucrose diet plus oral 
administration of 600 nmole/ kg/ day DAA-1 
starting from 24th week of the diet regime. 
 
Group 6 HFD + Ang-IV (24) - mice fed with high-fat-high-sucrose diet plus oral 
administration of 400 nmole/ kg/ day Ang-IV 





Five to 6-week old animals received ND and water ad libitum were treated orally with 
either DAA-1 (600 nmole/ kg/ day) or Ang-IV (400 nmole/ kg/ day). The animals were 
administered intraperitoneally either losartan (50 nmole/ kg/ day) or divininal-Ang-IV 
(300 nmole/ kg/ day) or indomethacin (200 nmole/ kg/ day). Indomethacin powder was 
directly dissolved in 0.1 M warm Na2CO3 in concentration of 0.1 mg/ ml and 
subsequently diluted to appropriate concentration in PBS (pH 7.2).  Control animals were 
similarly treated with water by oral gavage and PBS by intraperitoneal injection. Oral 
glucose tolerance test (OGTT) was performed every 2 weeks for a period of 4-8 weeks 






Oral glucose tolerance test (OGTT) was performed every 4 weeks. Animals were fasted 
overnight and the weight of individual animals was recorded prior to oral administration 
of 2 g/ kg glucose solution. Blood was taken from the orbital sinus of each animal 
immediately before glucose administration, and at 30, 60, and 120 min after the 
administration. The blood was allowed to clot before centrifugation. The serum was 
stored at -20 °C until assayed for glucose concentration using 150 volumes of Infinity 
Glucose Reagent (Thermo Electron Corp, Australia) in a 96-well plate and incubated for 
15 min at 37 °C. The amount of glucose was determined through an endpoint reaction 
and quantified with reference to a standard curve using a UV spectrometer at wavelength 




The assay measured serum fatty acids through a coupled reaction to determine the 
amount of non-esterified fatty acid (NEFA) purchased from Zen-Bio, North Carolina. 
Briefly, 5 !l of serum sample plus 45 !l dilution buffer were added into each well of a 96 
well plate. FFA Reagent A containing acyl-CoA synthetase (100 !l) was added to each 
well and placed in a 37 °C incubator for 10 min with gently shaking to ensure mixing. 
NEFA in the presence of Acyl-CoA synthetase is converted to acyl-CoA. FFA Reagent B 
containing acyl-CoA oxidase and peroxidase (50 !l) was then added into each well and 
incubated for 10 min, 37 °C. The acyl-CoA derivatives react with acyl-CoA oxidase to 
produce hydrogen peroxide, which will condense into a purple product that absorbs light 
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at 550 nm. The plate was allowed to equilibrate to room temperature for 5 min before the 
optical density of each well was measured using a UV spectrometer at 540 nm. The free 




The insulin ELISA assay kit was purchased from Crystal Chem, Illinois. Briefly, 5 !l of 
serum sample were pipetted into an antibody-coated microplate and incubated for 2 h at 4 
°C. The wells were washed extensively with wash buffer before dispensed 100 !l anti-
insulin enzyme conjugate per well and incubated for 30 min at room temperature. 
Following the incubation, the wells were washed and 100 !l of TMB enzyme substrate 
solution was added and incubated for 10 min at room temperature while avoiding 
exposure to light. The enzyme reaction was then stopped by adding 1N sulfuric acid. The 
absorbance was detected using an UV spectrometer with measuring wavelength 450 nm 
and subtracting wavelength 630 nm. Insulin concentrations were calculated with 









This index has been shown to correlate with the rate of whole-body glucose disposal 
during the euglycemic insulin clamp (Matsuda and DeFronzo 1999). 
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The animals were fasted overnight, injected intra-peritoneally with 40 U/ kg of insulin or 
equivalent volume of PBS and sacrificed by cervical dislocation 5 min after injection. 
The hind limb skeletal muscles were excised, immediately frozen in liquid nitrogen and 
stored in -80 °C until used for Western blotting studies. 
 
Skeletal muscle for GLUT4 translocation study were similarly prepared except that the 




Skeletal muscle tissue samples were fresh frozen in liquid nitrogen before mounted with 
Tissue-Tek Optimal Cutting Temperature Compound (Sakura, CA) onto a specimen 
block. The mounted samples were allowed to cool in a cryostat (Leica CM1850, TX) for 
10 min at -30 °C, before cutting into 20 !m-thick sections and picked up onto gelatin-
coated slides. The slides were warmed in room temperature for 30 min and fixed in cold 
acetone for 2 min. After fixation, the slides were washed with PBS and allowed to air-dry 
in room temperature for 1 h. Each sample was incubated with 2 !mol/ L dihydroethidium 
solution (Biotium, CA) for 30 min at 37 °C. Dihydroethidium is oxidized in the presence 
of ROS to form ethidium, which binds specifically to DNA in the nucleus and emit red 
fluorescence. In situ detections of superoxide in the skeletal muscles of the treated 
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animals were then carried out using fluorescence microscope and the intensity was 




Three to five grams of skeletal muscle were minced over ice pack and homogenized in 12 
volumes (wt/ vol) of ice-cold lysis buffer containing 50 mM HEPES/ NaOH (pH 7.5), 
150 mM NaCl, 2 mM EDTA, 10 % glycerol, 10 mM NaF, 2 mM Na4VO4, 1 mM 
phenylmethylsulfonylfluoride and 10 mM Na4P2O7 using a Polytron with high speed. The 
homogenate was centrifuged at 16,000 g for 10 min, 4 °C. The supernatant containing the 
solublized protein was collected and stored at -20 °C until used. All samples along with 
molecular-mass markers were subjected to SDS-PAGE using 10 % resolving gel in a 
constant voltage of 100 V for 2 h 30 min. The resolved proteins were then transferred 
electrophoretically onto nitrocellulose membrane, using Bio-Rad wet transfer cell in 100 
V for 1 h, 4 °C. The membrane was blocked with 5 % non-fat dried milk or Bovine 
Serum Albumin (BSA) for 1 h before incubation overnight at 4 ºC with either one of the 
following antibodies specific to gp91, pJNK, JNK 1/2 or actin. The membrane was then 
washed extensively in TBST (20 mM Tris. 137 mM NaCl, 0.1 % Tween 20, pH 7.5) for 
30 min. Respective HRP-conjugated secondary antibodies were added in TBST and 
incubated for 1 h. The TBST washing step was repeated and immunoreactive bands were 
detected by enhanced chemiluminescence method using SuperSignal West Pico 
Chemiluminescent Substrate kit (Thermo Scientific, IL). Autoradiography was carried 
using CL-XPosure film (Thermo Scientific, IL), with exposure time varied from 15 s to 
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10 min. The average band intensity was quantified by optical density using Bio-Rad 




Skeletal muscle tissue samples were prepared as previously described. Equal amount of 
solubilised skeletal muscle protein (1 mg) were incubated overnight at 4 °C in an end-
over-end rotor with anti-IR, anti-IRS-1, anti-IRAP, anti-PI3K or anti-AT1 receptor 
antibodies to a final concentration of 4 !g per mg of total protein for all antibodies. The 
immune complex was captured by adding 50 !l protein A-agarose beads (Calbiochem, 
Merck, Germany) for 4 h at 4 °C. The beads conjugated with the immune complex were 
pelleted at 15,000 g for 1 min at 4 °C and washed five times with lysis buffer to remove 
nonspecific binding proteins. The beads were then boiled in Laemmli sample buffer for 
10 min, and the protein A-agarose beads were removed from the denatured protein by 
centrifugation at 15,000 g for 1 min at 4 °C. The supernatant was assayed by Western 
blotting as described previously. Proteins immunoprecipitated with IR were 
immunoblotted with antibodies specific for phosphorylated tyrosine, phosphorylated 
serine, and IRS-1. Proteins immunoprecipitated with IRS-1 were immunoblotted with 
antibodies specific for phosphorylated tyrosine, IRS-1 phosphorylation at Serine 307, and 
PI3K. Proteins immunoprecipitated with IRAP were similarly immunoblotted with 
antibodies specific for phosphorylated tyrosine, phosphorylated serine, and PI3K. 
Proteins immunoprecipitated with PI3K were immunoblotted with antibodies specific 
IRAP. Proteins immunoprecipitated with AT1 receptor were immunoblotted with 
antibodies specific for JAK-2, IRS-1 and PI3K. The blots were stripped of bound 
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antibodies and reprobed with antibodies specific to IR, IRS-1, IRAP, PI3K and AT1 




The procedure used for membrane isolation was established using the methology of 
Dombrowski et al in 1996 with minor modifications. Three grams of frozen skeletal 
muscle was allowed to thaw and minced over an ice pack. The minced muscle was then 
homogenized with a Polytron using a low-speed setting in 45 ml of cold buffer containing 
10 mM sodium bicarbonate, 0.25 M sucrose, 5 mM sodium azide and 100 !M 
phenylmethylsulfonylfluoride. The homogenate was centrifuged at 1,300 g for 10 min. 
The supernatant was saved and the pellet collected to undergo another round of 
homogenizing and centrifugation. The supernatant from both spins were combined and 
centrifuged at 9,000 g for 10 min and the resulting supernatant was spun at 190,000 g for 
1 h. The pellet, containing the crude membranes was resuspended in 3 ml buffer and 
placed onto a discontinuous 25, 32 and 35 % wt/ wt sucrose gradient and centrifuged at 
150,000 g for 16 h. Prior to the centrifugation a sample of the pellet was collected for 
Western blot analysis to determine the total GLUT4 content. Fractions were collected and 
reconstituted in 200 !l sucrose-free buffer and spun at 190,000 g for 1 h (Figure 2.1). All 
centrifugations were carried out in 4 °C. The pelleted membrane fractions were 
resuspended in 200 !l buffer and kept at -20 °C until used for protein quantification, 









The protein concentrations of all test samples were determined by Bio-Rad DC Protein 
assay with appropriate dilution. Bovine Serum Albumin (BSA) purchased from Sigma 
was used as protein standard. A linear standard curve was determined using 8 
concentrations of BSA solution (0.2 mg/ ml to 1.8 mg/ ml). 20 !l of sample, 100 !l of 
reagent A and 800 !l of reagent B were pipetted into a curvette, mixed well, incubated 
for 15 min at room temperature and then measured with UV spectrometer at the 




The plasma concentrations of all test samples were determined by Alkaline 
Phosphodiesterase-1 assay. A linear standard curve was determined using 6 
concentrations of para-nitrophenol solution (25 !m/ ml to 125 !m/ ml). Fifty microlitre 
of sample was added to 0.2 ml of reaction buffer (1 M Na2CO3 /NaHCO3, pH 10.5, 1 % 
v/ v Triton-100, 20 mM thymine 5’ monophosphate (TMP) p-nitrophenol ester solution) 
and incubated for 30 min at 37 °C, followed by adding 0.25 ml of cold TCA and 1.5 ml 
of 2N NaOH to stop the reaction. The cleavage of TMP generates p-nitrophenol which is 
a yellow compound and its colour density was measured and quantified using a UV 
spectrometer at wavelength of 400 nm. The values of the PDE active were expressed in 





Goat polyclonal IgG antibody against gp91phox (SantaCruz, sc-5827; 1:200 dilution) 
Mouse monoclonal IgG antibody against phosphor-JNK (SantaCruz, sc-6254; 1:400 
dilution) Mouse monoclonal IgG antibody against JNK 1/ JNK 2 (BD Pharmingen, 
#554285, 1:1000 dilution) Rabbit polyclonal IgG antibody against Insulin R# (SantaCruz, 
sc-710; 1:400 dilution) Rabbit polyclonal IgG antibody against phospho-IRS-1 (Ser307) 
(SantaCruz, sc-33956-R; 1:800 dilution) Mouse monoclonal IgG antibody against 
phospho-Tyrosine (SantaCruz, sc-508; 1:400 dilution) Mouse monoclonal IgG antibody 
against IRS-1 (SantaCruz, sc-8038; 1:800 dilution) Mouse monoclonal IgG antibody 
against PI 3-kinase p85# (SantaCruz, sc-1637; 1:200 dilution) Rabbit polyclonal IgG 
antibody against phospho-Akt (Ser473) (Cell Signalling, #9271; 1:1000 dilution) Goat 
polyclonal IgG antibody against GLUT4 transporter (SantaCruz, sc-1608; 1:800 dilution) 
Mouse monoclonal IgM antibody against phosphor-Serine (SantaCruz, sc-81516; 1:200 
dilution) Rabbit polyclonal IgG antibody against AT1 (SantaCruz, sc-1173; 1:400 dilution) 
Goat polyclonal IgG antibody against JAK2 (SantaCruz, sc-34479; 1:400 dilution) Rabbit 
polyclonal IgG antibody against IRAP (Alpha Diagnostic, #IRAP11-A; 1:500 dilution) 
Mouse monoclonal IgG antibody against $-actin (Sigma, A2228; 1:2000 dilution) 
 
Goat anti-mouse IgG-HRP secondary antibody (SantaCruz, sc-2031; 1:10,000 to 20,000 
dilution) Goat anti-rabbit IgG-HRP secondary antibody (SantaCruz, sc-2004; 1:10,000 to 
20,000 dilution) Donkey anti-goat IgG-HRP secondary antibody (SantaCruz, sc-2020; 
1:10,000 to 15,000 dilution) Goat anti-mouse IgM-HRP antibody (SantaCruz, sc-2064; 
1:20,000 dilution) The list of antibodies is summarised in Table 2.2. 
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Beta–TC-6 insulin-secreting cells (ATCC, CRL-11506) were cultured in Dulbecco's 
Modified Eagle Medium (DMEM; ATCC, 30-2002) containing 100 U/ ml penicillin, 100 
!g/ ml streptomycin, and 15% fetal calf serum. The islets were grown to confluence in 25 
cm2 flasks (Nunc, EW-01930-48) and then rinsed, trypsinised and seeded into 96-well 




To analyse the effect of different glucose concentrations on the survival of the islets, 
beta-TC-6 cells were cultured in 96-well plate with DMEM for 4 days containing 
additional 5.5 mM, 11.1 mM, 33.3 mM or 100 mM glucose. The basal glucose 
concentration in the DMEM was 25 mM. For wells treated with DAA-I, Ang-IV or 
losartan, they were added into each well concurrent to the addition of glucose. PBS of 
similar volume was added for the control wells. DAA-I, Ang-IV and losartan were used 
at concentrations ranging from 10-16 to 10-6 M. The cell viability was determined after an 




After treatments, cell viability was assessed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma, M2003). Briefly, the cells were incubated 
with 0.5 mg/ ml MTT for approximately 1 h at 37ºC in dark. The medium was aspirated 
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and the formazan product solubilised with 100 !l dimethylsulfoxide. Viability was 






Data were expressed as mean ± SEM based on independent experiments. Statistical 
analysis was performed by student’s t-test for comparison between means, or one-way 
analysis of variance (ANOVA) for multiple testing. Probability values were considered 
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The animals were fed ND or HFD at six to seven weeks of age. At this age, the body 
weight was 21.1 ± 0.2 g in all groups (n = 60). As early as four weeks after the 
introduction of the diet regime, the body weight of the animals increased significantly 
more in the HFD mice (+6.2 ± 0.5 g) than in ND mice (+3.5 ± 0.3 g). Thereafter, the 
weight gain continued to be progressively higher in HFD mice compared to the ND 
counterparts (Figures 3.1.1 and 3.1.2). By the end of week 52, the HFD animals were 
almost two fold heavier compared to the ND animals with the average weights of 54.4 ± 
2.1 g and 32.2 ± 1.5 g, respectively (p < 0.05). 
 
The growth curve of HFD animals showed a pattern of larger weight gain over the first 
24 weeks, followed by a slower weight gain during the subsequent weeks. The growth 
curve of ND animals showed a similar pattern, with the larger weight gain in the first 8 
weeks. The average growth rate of ND and HFD animals during the 52-week study were 
0.22 ± 0.03 g/ week and 0.70 ± 0.06 g/ week, respectively (p < 0.05).  
 
Daily oral administration of DAA-1 (600 nmole/ kg) and Ang-IV (400 nmole/ kg) 
starting from week 0 or week 24 of the diet regime did not alter the weight gain and 





Figure 3.1.1 Effect of DAA-1 on the weight of C57BL/6J mice fed on HFD. Five to 6 
weeks old male animals were randomly divided into four groups of 10 animals.  Group 1 
animals were fed on a ND and administered vehicle (distilled water). Group 2 animals 
were fed on a HFD and administered vehicle.  Groups 3 and 4 animals were fed on a 
HFD and administered DAA-1 (600 nmole/ kg/ day) from 0 week and 24 week, 
respectively. Vehicle and DAA-1 solutions were administered orally by gavage in a 
volume of 0.1 ml. The weight of the animals was determined every 4 weeks for a 
duration of 52 weeks. Each value represents the mean ± SEM obtained from 10 
individual animals. *HFD, HFD + DAA-1 (0) and HFD + DAA-1 (24) significantly 





Figure 3.1.2 Effect of Ang-IV on the weight of C57BL/6J mice fed on HFD. Five to 6 
weeks old male animals were randomly divided into four groups of 10 animals.  Group 1 
animals were fed on a ND and administered vehicle (distilled water). Group 2 animals 
were fed on a HFD and administered vehicle. Groups 3 and 4 animals were fed on a HFD 
and administered Ang-IV (400 nmole/ kg/ day) from 0 week and 24 week, respectively. 
Vehicle and Ang-IV solutions were administered orally by gavage in a volume of 0.1 ml. 
The weight of the animals was determined every 4 weeks for a duration of 52 weeks. 
Each value represents the mean ± SEM obtained from 10 individual animals. *HFD, 
HFD + Ang-IV (0) and HFD + Ang-IV (24) significantly higher than ND. (p< 0.05, one 
way ANOVA, post hoc Fisher’s LSD).  
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The energy intake was greater in HFD animals when compared with the ND animals 
throughout the study period.  
 
HFD animals were found to consume higher amount of digestible energy after 32 weeks 
of feeding (p< 0.05). As shown in Figures 3.1.3 and 3.1.4, both DAA-1 and Ang-IV 
treated from week 0 or week 24 of the diet regime did not attenuate the animals’ food 
intake, as there were no significant differences among the HFD groups. Interestingly, a 
significant difference in body weight between the ND and HFD animals was detected as 
early as week 4 of the study, while the difference in energy consumed per body weight 
was observed on week 32 onwards. The data suggest that the dietary content is important 
in energy expenditure and storage as supported by previous dietary studies (Surwit, et al. 




Figure 3.1.3 Effect of DAA-1 on the energy of food consumed by C57BL/6J mice fed 
on HFD. The animals were those described in Figure 1.7. The food intake of the animals 
was determined every 4 weeks for a duration of 48 weeks. The calculation of the energy 
consumed was based on the weight of the food pellet consumed by the animals for a 24-h 
period. The value was multiplied by the amount of digestible energy given in Table 1 
(table of diet composition) divided by the weight of the animals.  Each value represents 
the mean ± SEM obtained from 10 individual animals. *HFD, HFD + DAA-1 (0) and 





Figure 3.1.4 Effect of Ang-IV on the energy of food consumed by C57BL/6J mice fed 
on HFD. The animals were those described in Figure 1.7. The food intake of the animals 
was determined every 4 weeks for a duration of 48 weeks. The calculation of the energy 
consumed was based on the weight of the food pellet consumed by the animals for a 24-h 
period. The value was multiplied by the amount of digestible energy given in Table 1 
(table of diet composition) divided by the weight of the animals.  Each value represents 
the mean ± SEM obtained from 10 individual animals. *HFD, HFD + Ang-IV (0) and 
HFD + Ang-IV (24) significantly higher than ND. (p< 0.05, one way ANOVA, post hoc 
Fisher’s LSD).  
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Fasting serum glucose level above 10 mM is used as an indication for pre-diabetes and 
T2DM. The HFD animals were found to have significant increase in fasting serum 
glucose after 4 weeks of feeding (6.6 ± 0.2 mM) compared to the ND animals (3.5 ± 0.5 
mM). The fasting serum glucose of the HFD animals continued to escalate sharply up to 
24th week of feeding and peaked at 11.8 ± 0.8 mM. Thereafter, the fasting serum glucose 
of the HFD animals remained relatively stable and was 10.4 ± 0.4 mM at the end of 48 
weeks, about seventy percent higher to that of ND animals (6.1 ± 0.5 mM) (p< 0.05).  
 
From Figures 3.1.5 and 3.1.6, the following observations on the effects of DAA-1 and 
Ang-IV on fasting serum glucose level of HFD animals were made: 
 
1. The fasting serum glucose of HFD + DAA-1 (0) and HFD + Ang-IV (0) animals 
were significantly higher compared to the ND control animals from week 4 and 
week 8 onwards, respectively.  
 
2. Although the HFD + DAA-1 (0) animals showed lower fasting serum glucose  
when compared with the HFD control animals from week 16 onwards, the 
differences were not significant except on 28 and 32 week. 
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3. HFD + Ang-IV (0) animals showed significant lower fasting serum glucose on 
week 4 compared to the HFD control animals but the difference was not 
significant albeit lower levels from week 8 onwards.  
 
4. HFD + DAA-1 (24) animals did not show any difference in fasting serum glucose 
when compared to the HFD control animals. 
 
5. HFD + Ang-IV (24) animals showed significant lower fasting serum glucose on 
week 32 (8 weeks after the introduction of peptide treatment) compared to the 
HFD control animals, but the difference was not significant albeit lower levels 
from week 36 onwards. 
 
Although some of the DAA-1 and Ang-IV treated HFD animals exhibited lower fasting 
serum glucose level compared to the HFD control group, daily oral administration of 
DAA-1 (600 nmole/ kg) and Ang-IV (400 nmole/ kg) starting from week 0 or week 24 
did not seem to alter the fasting serum glucose in HFD animals. After 8 weeks of feeding, 
the fasting serum glucose of the all HFD groups remained higher than the ND control 






Figure 3.1.5 Effect of DAA-1 on fasting blood glucose profile in C57BL/6J mice fed 
on HFD. Animals were those described in Figure 1.7 (52 weeks data were not available 
as animals were treated with insulin before sacrificed for cellular work). Serum glucose 
was determined after a 16-h overnight fast. Each value represents the mean ± SEM 
obtained from 10 individual animals. *HFD significantly higher than ND. #HFD + DAA-
1 (0) and HFD + DAA-1 (24) significantly higher than ND. ^HFD + DAA-1 (0) 




Figure 3.1.6 Effect of Ang-IV on fasting blood glucose profile in C57BL/6J mice fed 
on HFD. Animals were those described in Figure 1.7 (52 weeks data were not available 
as animals were treated with insulin before sacrificed for cellular work). Serum glucose 
was determined after a 16-h overnight fast. Each value represents the mean ± SEM 
obtained from 10 individual animals. *HFD significantly higher than ND. #HFD + Ang-
IV (0) and HFD + Ang-IV (24) significantly higher than ND. ^HFD + Ang (0) and HFD 
+ Ang-IV (24) significantly lower than HFD. (p< 0.05, one way ANOVA, post hoc 





Serum glucose level at 30 min of OGTT above 20 mM is used as an indication for pre-
diabetes and T2DM. The HFD animals were found to have a significant increase in 30 
min OGTT serum glucose after 8 weeks of feeding (20.3 ± 0.5 mM) compared to the ND 
animals (14.8 ± 0.5 mM). Thereafter, the 30 min OGTT serum glucose of the HFD 
animals continued to rise in a constant rate and remained significantly higher than the ND 
animals throughout the study. At the end of 48 week, the value of the 30 min OGTT 
serum glucose of the HFD control animals was 25.5 ± 0.6 mM, about fifty percent higher 
to that of their ND counterparts (17.1 ± 0.4 mM) (p< 0.05).  
 
From Figures 3.1.7 and 3.1.8, the following observations on the effects of DAA-1 and 
Ang-IV on 30 min OGTT serum glucose level of HFD animals were made: 
 
1. HFD + DAA-1 (0) and HFD + Ang-IV (0) animals showed significant lower 30 
min OGTT serum glucose compared to the HFD control animals on week 24 and 
20 onwards, respectively, and the trend continued until the end of the study. At 
the end of the 48 week, the 30 min OGTT serum glucose level of the HFD + 
DAA-1 (0) animals (19.3 ± 1.1 mM) and HFD + Ang (0) animals (18.7 ± 1.0 mM) 
were lower than that of HFD diabetic animals (p< 0.05) and interestingly, 
comparable to the healthy ND animals.  
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2. HFD + DAA-1 (24) and HFD Ang-IV (24) animals exhibited significantly lower 
30 min OGTT serum glucose compared to the HFD control group from week 32 
and 28 onwards, respectively (8 weeks and 6 weeks after the administration of the 
peptide treatments). Similar to the animals treated with the peptides from week 0, 
the hypoglycaemic effect of the peptides was persistent throughout the study. At 
the end of 48 weeks, HFD + DAA-1 (24) and HFD Ang-IV (24) animals, with 
values of 19.5 ± 0.5 mM and 19.1 ± 0.7 mM respectively, displayed significantly 
lower 30 min OGTT blood glucose compared to the HFD diabetic animals and 
significantly higher compared to ND healthy animals.  
 
The 30 min OGTT blood glucose level measures the efficiency of glucose uptake by the 
animals after glucose load. The data seem to suggest that the hypoglycaemic actions of 
DAA-1 and Ang-IV are effective in both pre-diabetic and diabetic HFD animals. In 
addition, DAA-1 had later onset of hypoglycaemic action compared to Ang-IV, which 






Figure 3.1.7 Effect of DAA-1 on 30-mim OGTT profile in C57BL/6J mice fed on 
HFD. Animals were those described in Figure 1.7 (52 weeks data were not available as 
animals were treated with insulin before sacrificed for cellular work). Serum glucose was 
determined after a 16-h overnight fast and 30 min after the glucose load. Each value 
represents the mean ± SEM obtained from 10 individual animals. *HFD significantly 
higher than ND. #HFD + DAA-1(0) and HFD + DAA-1(24) significantly higher than ND. 
^HFD + DAA-1(0) and HFD + DAA-1(24) significantly lower than HFD. (p< 0.05, one 




Figure 3.1.8 Effect of Ang-IV on 30-mim OGTT profile in C57BL/6J mice fed on 
HFD. Animals were those described in Figure 1.7 (52 weeks data were not available as 
animals were treated with insulin before sacrificed for cellular work). Serum glucose was 
determined after a 16-h overnight fast and 30 min after the glucose load. Each value 
represents the mean ± SEM of 10 individual animals. *HFD significantly higher than ND. 
#HFD + Ang-IV (0) and HFD + Ang-IV (24) significantly higher than ND. ^HFD + Ang-
IV (0) and HFD + Ang-IV (24) significantly lower than HFD. (p< 0.05, one way 





Figure 3.1.9 shows the OGTT full profile of the serum glucose level of the test animals at 
48 week. The OGTT Area under Curve (AUC) for serum glucose of HFD animals (2027 
± 142 mM) was found to be significantly higher than ND animals (1523 ± 87 mM). 
Similarly, the serum glucose levels in all time points of the OGTT (0, 30, 60 and 120 min) 
were higher in HFD control animals (p< 0.05). 
 
With regards to the effects of DAA-1 and Ang-IV on the full profile of the serum glucose 
level in OGTT: 
 
1. HFD + DAA-1 (0) and HFD + Ang-IV (0) animals had significant lower AUC 
values (1589 ± 186 mM and 1511 ± 190 mM, respectively) compared to the HFD 
control animals. Despite high fasting glucose levels, these animals displayed 
significantly lower serum glucose after glucose load at 30, 60 and 120 min 
compared to the HFD control animals. In addition, these values were comparable 
to the non-diabetic ND animals.  
 
2. HFD + DAA-1 (24) and HFD + Ang-IV (24) animals displayed significantly 
lower AUC (1657 ± 131 mM and 1611 ± 122 mM, respectively) compared to the 
HFD control animals. Similar to the animals treated with the peptides on week 0, 
these animals showed higher fasting glucose levels compared to ND animals (p< 
0.05). After glucose load, HFD + DAA-1 (24) and HFD + Ang-IV (24) had 
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significant lower serum glucose compared to the HFD control animals at 30, 60 
and 120 min. With the exception of 30 min time point, these values were 
comparable to the non-diabetic ND animals.  
 
Interestingly, chronic treatment of DAA-1 and Ang-IV did not attenuate the fasting 
serum glucose level of the HFD animals, but improved the glucose uptake in OGTT. The 
effect was observed in both pre-diabetic and diabetic HFD animals treated from week 0 
and 24, respectively. In addition, the data seems to suggest that concurrent treatment of 
the peptides and HFD from week 0 was more effective with lower AUC values and 30 
min serum glucose levels compared to the HFD animals that received treatment from 24 






Figure 3.1.9 Effects of DAA-1 and Ang-IV on the OGTT of C57BL/6J mice fed on 
HFD. Animals were those described in Figure 1.7. The OGTT was performed on animals 
that were fed on HFD for 48 weeks. The vertical bars represent the SEM of mean values 
obtained from 10 individual animals. *Significantly higher than the corresponding value 
of the ND animals. #Significantly lower than the corresponding value of the HFD animals 





Hyperinsulinemia is one of the hallmarks of T2DM, where insulin secretion is increased 
in response to rising blood glucose. The serum insulin concentration of the test animals 
was measured every eight weeks. HFD animals were found to have significant increased 
fasting serum insulin after 16 weeks of feeding (0.93 ± 0.19 ng/ ml) compared to the ND 
animals (0.34 ± 0.05 ng/ ml). The fasting serum insulin of the HFD animals continued to 
increase gradually until the end of the study. The ND animals did not demonstrate any 
increase in fasting serum insulin over the study period. At the end 48 weeks, the fasting 
serum insulin of the HFD animals was three-fold higher than that of the ND animals 
(1.28 ± 0.24 ng/ ml versus 0.38 ± 0.14 ng/ ml) (p< 0.05).  
 
As shown in Figures 3.1.10 and 3.1.11, daily oral administration of DAA-1 and Ang-IV 
starting from week 0 or week 24 did not seem to alter the fasting serum insulin in HFD 
animals. From 16 week of feeding onwards, the fasting serum insulin of the all HFD 
groups remained significantly higher than the ND control group throughout the study. 
The trend was similar to that of fasting serum glucose concentration (Figures 3.1.5 and 
3.1.6). Notably, HFD animals developed significant increase in fasting serum glucose and 
insulin at 4 and 16 week of feeding, respectively, suggesting the development of 








Figure 3.1.10 Effect of DAA-1 on fasting blood insulin profile in C57BL/6J mice fed 
on HFD. Animals were those described in Figure 1.7 (52 weeks data were not available 
as animals were treated with insulin before sacrificed for cellular work). Serum insulin 
was determined after a 16-h overnight fast. Each value reprsents the mean ± SEM 
obtained from 10 individual animals. *HFD, HFD + DAA-1 (0) and HFD + DAA-1 (24) 




Figure 3.1.11 Effect of Ang-IV on fasting blood insulin profile in C57BL/6J mice fed 
on HFD. Animals were those described in Figure 1.7 (52 weeks data were not available 
as animals were treated with insulin before sacrificed for cellular work). Serum insulin 
was determined after a 16-h overnight fast. Each value represents the mean ± SEM 
obtained from 10 individual animals. *HFD, HFD + Ang-IV (0) and HFD + Ang-IV (24) 





After the glucose load, it was observed that the serum insulin level of HFD animals in all 
groups remained higher than ND animals at all time points and no significant difference 
was detected among the peptide-treated HFD animals (Figure 3.1.12). In contrast to 
Figure 3.1.9, the DAA-1 and Ang-IV treated HFD animals showed increased glucose 
uptake after glucose load. The data suggest that the hypoglycaemic action was not 
accompanied by an increase in serum insulin level of the peptide-treated HFD animals, 
and that the peptides exert hypoglycaemic action in HFD animals by attenuating insulin 
resistance or sensitivity. The result supports the finding that DAA-1 is not an insulin 





Figure 3.1.12 Effects of DAA-1 and Ang-IV on the serum insulin profile of 
C57BL/6J mice fed on a HFD. Animals were those described in Figure 1.7. The insulin 
assay was carried out in serum samples obtained during the OGTT on animals that were 
fed on HFD for 48 weeks. The vertical bars represent the SEM of mean values obtained 
from 10 individual animals. *Significantly higher than the corresponding value of the ND 






The fasting serum FFA level was measured at 0, 24 and 48 week (Figure 3.1.13). At the 
start of the study, the fasting serum FFA levels in all groups were similar. After 24 weeks 
of feeding, the fasting serum FFA level of the HFD animals (641 ± 31 !M) was almost 
two-fold higher compared to the ND animals (340 ± 20 !M) (p< 0.05). Interestingly, the 
HFD + DAA-1 (0) and HFD + Ang-IV (0) animals  (552 ± 33 !M and 417 ± 27 !M, 
respectively) showed significant lower fasting serum FFA levels compared with the HFD 
diabetic animals, but higher when compared with the ND healthy animals (p< 0.05). 
However, at the end of 48 weeks, the fasting serum FFA level of ND animals matched 
those of in the HFD animals, and no significant difference was observed among the six 
groups. It is known that the serum FFA level of the animals increase as they age (Tucker 
and Turcotte 2002) 
 
The data suggest that chronic oral administration of DAA-1 and Ang-IV starting from 
week 0 seems to attenuate the HFD-induced increase in serum FFA at 24 week. However, 
the serum FFA continued to increase regardless of the diet type and chronic treatment of 




Figure 3.1.13 Effects of DAA-1 and Ang-IV on fasting serum free fatty acid of 
C57BL/6J mice fed on HFD. Free fatty acid assay was carried out in blood sample 
obtained at 0 min (fasting level) of the OGTT. The vertical bars represent the SEM of 
mean values obtained from 10 individual animals. *Significantly higher than the 
corresponding value of the ND animals. #Significantly lower than the corresponding 
value of the HFD animals (p< 0.05, one way ANOVA, post hoc Fisher’s LSD).   
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At the end of 48 week, the value of non-fasting serum glucose of the HFD control 
animals was 9.2 ± 0.3 mM, about thirty percent higher than that of their ND counterparts 
(7.0 ± 0.4 mM). HFD + DAA-1 (0) and HFD + Ang-IV (0) animals showed significant 
lower non-fasting serum glucose compared to the HFD control group (7.8 ± 0.2 mM and 
8.0 ± 0.4 mM, respectively). Similarly, HFD + DAA-1 (24) and HFD + Ang-IV (24) 
animals exhibited lower levels of non-fasting serum glucose (7.7 ± 0.3 mM and 7.5 ± 0.2 
mM, respectively) (p< 0.05). Interestingly, the non-fasting serum glucose values of the 
both DAA-1 and Ang-IV treated HFD animals (starting from week 0 and week 24) were 
not significantly different from the ND control animals (Table 3.1.1). 
 
The data suggest that chronic oral administration of DAA-1 and Ang-IV starting from 
week 0 or week 24 seem to exert hypoglycaemic effect on the HFD diabetic animals and 
the non-fasting serum glucose concentration of these animals are comparable to the ND 
healthy animals.  
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Table 3.1.1 summarises the parameters measured at the end of 48 weeks. The whole body 
insulin sensitivity of the animals was calculated using the values of fasting serum glucose 
and insulin levels and mean serum glucose and insulin levels during OGTT. The HFD 
animals were found to have an insulin sensitivity index of 620 ± 96, five times lower to 
that of the ND animals (3219 ± 316) (p< 0.05). Whereas, HFD + DAA-1 (0) and HFD + 
Ang-IV (0) animals showed significant higher values compared to the HFD control group 
(944 ± 75 and 1018 ± 122, respectively). Similarly, HFD + DAA-1 (24) and HFD + Ang-
IV (24) animals exhibited significantly lower values of 1011 ± 94 and 884 ± 86, 
respectively. However, when compared with the ND control animals, the insulin 
sensitivity indexes of DAA-1 and Ang-IV treated HFD animals (starting from week 0 and 
week 24) were three fold lower (p< 0.05). It is noted that the average value of the insulin 
sensitivity index was greater in the HFD + DAA-1 (24) animals compared to their HFD + 
DAA-1 (0) counterparts, despite shorter duration of peptide treatment. The difference 
was not statistically significant with p value between these groups more than 0.05, which 
may be a consequence of inter-individual variation among the animals.  
 
The data show that DAA-1 and Ang-IV significantly increased the whole body insulin 
sensitivity in HFD animals.  
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Values represent mean ± SEM obtained from 10 individual animals. *Significantly 
different from the value of ND. #Significantly different from the value of HFD (p< 0.05, 
one way ANOVA, Fisher’s LSD). Insulin Sensitivity Index = 10000/ {([glucose]0min X 
[insulin]0min X (G X I)}
1/2.  G = mean blood glucose of 120 min OGTT; I = mean blood 
insulin of 120 min OGTT.  
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At the end of 52 weeks, the animals were sacrificed after given intraperitoneal injection 
of either insulin or PBS. The hind limb skeletal muscles were excised and used for insulin 
signaling study by Western blotting. Various crucial components of the insulin signaling 
pathway were examined as depicted in Figure 3.2.1: 
 
1. Insulin receptor 
a. Inhibitory serine phosphorylation of IR 
b. Insulin-induced tyrosine phosphorylation of IR 
 
2. Insulin receptor substrate-1 
a. Inhibitory serine phosphorylation of IRS-1 
b. Insulin-induced tyrosine phosphorylation of IRS-1 
 
3. Insulin-induced PI3K attachment to IRS-1 
 
4. Insulin-induced protein kinase B activation (pAkt) 
 






Figure 3.2.1 Experimental outline for the study of the effects of chronic treatment of 
DAA-1 and Ang-IV on insulin signal transduction in the skeletal muscles of HFD 
animals. 1- inhibitory serine phosphorylation and insulin-induced tyrosine 
phosphorylation of IR; 2- inhibitory serine phosphorylation and insulin-induced tyrosine 
phosphorylation of IRS-1; 3- insulin-induced PI3K attachment to IRS-1; 4- insulin-
induced protein kinase B activation; 5- insulin-induced GLUT4 translocation to plasma 
membrane.  
 90 




As shown in Figure 3.2.2, animals fed on one-year HFD showed significantly increased 
serine phosphorylation of IR in both basal and upon insulin stimulation in the skeletal 
muscle, compared to the ND animals. The increase was almost four fold. The tissues of 
DAA-1 treated HFD animals (starting from week 0 and 24) showed decreased serine 
phosphorylation of IR compared to HFD control animals (p< 0.05). The decrease was 
almost two fold and observed in both basal and insulin stimulation skeletal muscles. 
However, the levels of tissue IR serine phosphorylation of DAA-1 and Ang-IV treated 
HFD animals were significantly higher by at least two fold compared to the healthy ND 
animals. The IR serine phosphorylation levels in Ang-IV treated HFD animals (starting 
from week 0 and 24) were lower compared to the HFD control, but not significant (p> 
0.05).  
 
DAA-1 but not Ang-IV significantly attenuated the increased basal and insulin-induced 
levels of serine phosphorylated IR inhibition in the skeletal muscles of the HFD mice. 




Figure 3.2.2 Effects of DAA-1 and Ang-IV on basal and insulin-stimulated serine 
phosphorylation of IR in skeletal muscle of C57BL/ 6J mice fed on HFD at the end 
of 52 weeks. Animals were fasted for 16 hours (overnight) and intraperitoneally 
administered with either insulin solution (40 U/ kg) or equivalent volume of PBS.  
Animals were sacrificed by cervical dislocation 5 minutes later. The hind limb muscles 
were excised. IR protein was immunoprecipitated (IP) from muscle supernatant with IR 
antibody overnight. The conjugate were then incubated with protein A-agarose beads. 
Isolated IR protein (1000 µg) was then resolved through SDS-PAGE, and immunoblotted 
(IB) with pSer and IR antibodies for Western Blot analysis. Upper panel shows 
representative data of pSer and IR. Bottom panel: pSer content expressed against the total 
IR content. The vertical bars represent the SEM of samples obtained from 3 individual 
animals, assigning a value of 100 % to the non-insulin treated ND control. *Significantly 
different from corresponding animals fed with ND. #Significantly different from 
corresponding animals fed with HFD. (p< 0.05, one way ANOVA, Fisher’s LSD) 
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After 52 weeks of HFD, there were no differences in basal IR tyrosine phosphorylation 
among the skeletal muscles of ND and all HFD groups (Figure 3.2.3). Despite this 
observation, the tissues of HFD control animals showed significantly reduced insulin-
stimulated IR tyrosine phosphorylation, compared with the ND control animals. The 
reduction was almost forty percent (p< 0.05). In parallel to the extent of IR serine 
phosphorylation, it was shown that DAA-1 treated but not Ang-IV treated HFD animals 
showed significantly attenuated insulin-stimulated IR tyrosine phosphorylation in the 
skeletal muscles, compared with HFD control animals. Remarkably, the magnitude of 
increase in DAA-1 treated HFD animals (starting from week 0 and 24) were comparable 
to the ND healthy animals. The insulin-stimulated IR tyrosine phosphorylation in the 
tissues of Ang-IV treated HFD animals (starting from week 0 and 24) were found to be 
significantly lower than ND control.  
 
DAA-1 but not Ang-IV significantly improved insulin-induced IR tyrosine 
phosphorylation in HFD mice. The findings support the hypothesis that insulin signalling 
is negatively modulated by increased phosphorylation of IR in serine residues. The 
amount of IR serine phosphorylation seems to determine the degree of inhibition on 




Figure 3.2.3 Effects of DAA-1 and Ang-IV on basal and insulin-stimulated tyrosine 
phosphorylation of IR in skeletal muscle of C57BL/6J mice fed on HFD at the end of 
52 weeks. Animals were fasted for 16 hours (overnight) and intraperitoneally 
administered with either insulin solution (40 U/ kg) or equivalent volume of PBS.  
Animals were sacrificed by cervical dislocation 5 minutes later. The hind limb muscles 
were excised. IR protein was immunoprecipitated (IP) from muscle supernatant with IR 
antibody overnight. The conjugate were then incubated with protein A-agarose beads. 
Isolated IR protein (1000 µg) was then resolved through SDS-PAGE, and immunoblotted 
(IB) with pTyr and IR antibodies for Western Blot analysis. Upper panel shows 
representative data of pSer and IR. Bottom panel: pTyr content expressed against the total 
IR content. The vertical bars represent the SEM of samples obtained from 3 individual 
animals, assigning a value of 100 % to the non-insulin treated ND control. *Significantly 
different from corresponding animals fed with ND. #Significantly different from 
corresponding animals fed with HFD. (p< 0.05, one way ANOVA, Fisher’s LSD) 
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In parallel to increased levels of IR serine phosphorylation in HFD animals, there was 
increase in both basal and insulin-stimulated IRS-1 serine phosphorylation at amino acid 
residue position 307 in the muscles of HFD animals when compared with ND control 
animals.  In Figure 3.2.4, the increase was shown to be about three and a half fold. The 
tissues of DAA-1 but not Ang-IV treated HFD animals (starting from week 0 and 24) 
showed significantly decreased serine phosphorylation of IRS-1 in both basal and insulin 
stimulation, compared to the HFD control animals. However, the levels of IRS-1 serine 
phosphorylation of DAA-1 and Ang-IV treated HFD animals’ muscles were higher when 
compared to the ND control animals (p< 0.05). Similar to previous data, Ang-IV treated 
HFD animals (starting from week 0 and 24) showed lower, but not significant IRS-1 
serine phosphorylation in the skeletal muscles when compared when the HFD diabetic 
animals.  
 
The results support the notion that physiological conditions like obesity, hyperglycemia 
and hyperinsulinemia activate several serine and threonine kinases, cause serine 
phosphorylation of IR and IRS-1, and impair insulin signalling in T2DM. DAA-1 seems 
to exert its hypoglycaemic effect by attenuating the skeletal muscle levels of serine 




Figure 3.2.4 Effects of DAA-1 and Ang-IV on basal and insulin-stimulated serine 
phosphorylation of IRS-1 in skeletal muscle of C57BL/6J mice fed on HFD at the 
end of 52 weeks. Animals were fasted for 16 hours (overnight) and intraperitoneally 
administered with either insulin solution (40 U/ kg) or equivalent volume of PBS.  
Animals were sacrificed by cervical dislocation 5 minutes later. The hind limb muscles 
were excised. IRS-1 protein was immunoprecipitated (IP) from muscle supernatant with 
IRS-1 antibody overnight. The conjugate were then incubated with protein A-agarose 
beads. Isolated IRS-1 protein (1000 µg) was then resolved through SDS-PAGE, and 
immunoblotted (IB) with pIRS-1ser307 and IRS-1 antibodies for Western Blot analysis. 
Upper panel shows representative data of pIRS-1ser307 and IRS-1. Bottom panel: pIRS-
1ser307 content expressed against the total IRS-1 content. The vertical bars represent the 
SEM of samples obtained from 3 individual animals, assigning a value of 100 % to the 
non-insulin treated ND control. *Significantly different from corresponding animals fed 
with ND. #Significantly different from corresponding animals fed with HFD. (p< 0.05, 
one way ANOVA, Fisher’s LSD) 
 96 
CQBQA& 0((%P+,& '(& PM4'*1P& +4%"+K%*+& '(& @..T:& "*O& .*RT=W& '*& "P+12"+'4L&
=85T:& +L4',1*%&NM',NM'4L$"+1'*& 1*& +M%&,Y%$%+"$&KJ,P$%,&'(&;F@&"*1K"$,&
"+&GB&Z%%Y&
 
High serine phosphorylation of IRS-1 at amino acid residue position 307 in diabetics is 
found to induce a conformational change that reduces its binding affinity for IR and IRS-
1 tyrosine phosphorylation. In agreement to the previous data, Figure 3.2.5 shows that 
there were no differences in the basal IRS-1 tyrosine phosphorylation among the skeletal 
muscles of ND and all HFD groups. Concomitant to the extent of serine phosphorylation 
of IRS-1, the muscles of the HFD control animals showed a significant fifty percent 
reduction in insulin-stimulated IRS-1 tyrosine phosphorylation, compared with the ND 
control animals. Similarly, the tissues of DAA-1 but not Ang-IV treated HFD animals 
showed improved insulin-stimulated IRS-1 tyrosine phosphorylation, compared with 
HFD control animals (p< 0.05). The magnitude of increase in DAA-1 treated HFD 
animals (starting from week 0 and 24) were similar to that of ND control. In contrast, the 
insulin-stimulated IRS-1 tyrosine phosphorylation in the muscles of Ang-IV treated HFD 
animals (starting from week 24) was found to be significantly lower than the healthy ND 
animals.  
 
DAA-1 but not Ang-IV is shown to significantly improve insulin-induced IRS-1 tyrosine 
phosphorylation in the skeletal muscles of HFD mice and the extent of improvement was 




Figure 3.2.5 Effects of DAA-1 and Ang-IV on basal and insulin-stimulated tyrosine 
phosphorylation of IRS-1 in skeletal muscle of C57BL/6J mice fed on HFD at the 
end of 52 weeks. Animals were fasted for 16 hours (overnight) and intraperitoneally 
administered with either insulin solution (40 U/ kg) or equivalent volume of PBS.  
Animals were sacrificed by cervical dislocation 5 minutes later. The hind limb muscles 
were excised. IRS-1 protein was immunoprecipitated (IP) from muscle supernatant with 
IRS-1 antibody overnight. The conjugate were then incubated with protein A-agarose 
beads. Isolated IRS-1 protein (1000 µg) was then resolved through SDS-PAGE, and 
immunoblotted (IB) with pTyr and IRS-1 antibodies for Western Blot analysis. Upper 
panel shows representative data of pTyr and IRS-1. Bottom panel: pTyr content 
expressed against the total IRS-1 content. The vertical bars represent the SEM of samples 
obtained from 3 individual animals, assigning a value of 100 % to the non-insulin treated 
ND control. *Significantly different from corresponding animals fed with ND. 
#Significantly different from corresponding animals fed with HFD. (p< 0.05, one way 
ANOVA, Fisher’s LSD) 
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Upon insulin stimulation, tyrosine phosphorylated IRS-1 generates docking sites for 
binding and activation of PI3K, which activates insulin signalling. In parallel to the IRS-1 
tyrosine phosphorylation, the insulin-stimulated IRS-1/ PI3K association in the skeletal 
muscles of the HFD control animals was significantly impaired when compared to their 
ND counterparts (p< 0.05). As expected, this impairment was significantly attenuated in 
DAA-1 treated HFD animals (starting from week 0 and 24) but not Ang-IV treated HFD 
animals (Figure 3.2.6). Notably, tissues of the DAA-1 treated animals showed similar 
degree of insulin-stimulated IRS-1/ PI3K association to the ND control. HFD animals 
treated with Ang-IV, however, demonstrated lesser extent of tissues insulin-stimulated 
IRS-1/ PI3K association compared to the DAA-1 treated counterparts and the differences 
when compared to both ND and HFD controls, were not significant.  
 
Taken together, HFD was shown to increase serine phosphorylation of IR and IRS-1, 
decrease insulin-stimulated tyrosine phosphorylation of IR and IRS-1, and association of 
IRS-1 and PI3K in the skeletal muscles of the animals. DAA-1 but not Ang-IV was 




Figure 3.2.6 Effects of DAA-1 and Ang-IV on basal and insulin-stimulated 
attachment of PI3K to IRS-1 in skeletal muscle of C57BL/6J mice fed on HFD at the 
end of 52 weeks. Animals were fasted for 16 hours (overnight) and intraperitoneally 
administered with either insulin solution (40 U/ kg) or equivalent volume of PBS.  
Animals were sacrificed by cervical dislocation 5 minutes later. The hind limb muscles 
were excised. IRS-1 protein was immunoprecipitated (IP) from muscle supernatant with 
IRS-1 antibody overnight. The conjugate were then incubated with protein A-agarose 
beads. Isolated IRS-1 protein (1000 µg) was then resolved through SDS-PAGE, and 
immunoblotted (IB) with PI3K and IRS-1 antibodies for Western Blot analysis. Upper 
panel shows representative data of PI3K and IRS-1. Bottom panel: PI3K content 
expressed against the total IRS-1 content. The vertical bars represent the SEM of samples 
obtained from 3 individual animals, assigning a value of 100 % to the non-insulin treated 
ND control. *Significantly different from corresponding animals fed with ND. 
#Significantly different from corresponding animals fed with HFD. (p< 0.05, one way 
ANOVA, Fisher’s LSD) 
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PI3K activation increases serine phosphorylation of Akt, which in turn stimulates the 
glucose transport in the muscle. In Figure 3.2.7, it is interesting to note that the tissues of 
HFD diabetic animals showed more than fifty percent decreases in basal and insulin-
stimulated Akt serine phosphorylation compared to the ND healthy animals (p< 0.05). 
The basal Akt activity was significantly decreased when compared to the PI3K coupling 
to IRS-1 in HFD animals, similar effects were reported in other diabetic animal studies 
(Lee, et al. 2009; Reiter, et al. 2006). In contrast, the skeletal muscles of the HFD animals 
treated with DAA-1 and Ang-IV (starting from week 0 and 24), showed restored levels in 
basal and insulin-stimulated Akt activation. Interestingly, the magnitude of insulin-
stimulated Akt activation in Ang-IV treated HFD animals (starting from week 0 and 24) 
was more than thirty percent greater than the ND healthy animals (p< 0.05). The finding 
was unexpected given that the upstream components of Akt activation were not 
attenuated in the skeletal muscles of HFD animals treated with Ang-IV, as shown in 
previous figures.  
 
Both DAA-1 and Ang-IV restored basal Akt activity in HFD animals. Concomitant to the 
PI3K activation, DAA-1 improved insulin-stimulated Akt serine phosphorylation in the 
skeletal muscles of HFD animals. However, Ang-IV induced significantly greater insulin-
stimulated Akt serine phosphorylation despite the lack of any corresponding increase in 
IRS-1/ PI3K association. The data suggest that Ang-IV induces insulin-stimulated Akt 




Figure 3.2.7 Effects of DAA-1 and Ang-IV on basal and insulin-stimulated 
phosphorylation of Akt in skeletal muscle of C57BL/6J mice fed on HFD at the end 
of 52 weeks. Animals were fasted for 16 hours (overnight) and intraperitoneally 
administered with either insulin solution (40 U/ kg) or equivalent volume of PBS.  
Animals were sacrificed by cervical dislocation 5 minutes later. The hind limb muscles 
were excised and 400 µg (pAkt) and 30 µg (actin) of protein lysate were subjected to 
SDS-PAGE. Upper panel shows the representative data of pAkt Ser473 and actin. Bottom 
panel: pAkt Ser473 content expressed against the actin content.  The vertical bars represent 
the SEM of samples obtained from 3 individual animals, assigning a value of 100 % to 
the non-insulin treated ND control. *Significantly different from corresponding animals 
fed with ND. #Significantly different from corresponding animals fed with HFD. (p< 0.05, 
one way ANOVA, Fisher’s LSD)  
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As shown in Figure 3.2.8, the distribution of GLUT4 protein vis a vis alkaline 
phosphodiesterase-1 activity in membranes of different sucrose gradient fractions. The 
alkaline phosphodiesterase activity, a marker for plasma membranes was the highest in 
the 25 % sucrose gradient, and this fraction was used in subsequent experiments on 
plasma membranes. 
 
The activation of Akt initiates a downstream signalling cascade leading to the 
translocation of GLUT4 from the intracellular vesicular store into plasma membrane. In 
relation to the Akt activation in Figure 3.2.7, the insulin stimulated skeletal muscles of 
ND healthy animals showed a two and a half fold increase in GLUT4 content in the 
plasma membrane fraction and the increase was impaired in the HFD diabetic animals 
(Figure 3.2.9). The skeletal muscles of HFD animals treated with DAA-1 and Ang-IV 
(starting from week 0 and 24) showed restored levels of insulin-stimulated GLUT4 
translocation similar to ND control animals. There were no differences in the total 
GLUT4 protein expressions among the skeletal muscles of all groups (Figure 3.2.9). The 
data support the findings from previous studies that insulin-stimulated conditions 
decrease the cell surface GLUT4 without affecting the total cellular GLUT4 content in 
diabetic conditions (Garvey, et al. 1987).  
 
The data suggest that both chronic treatments of DAA-1 and Ang-IV (starting from week 
0 and 24) potentiated insulin-induced GLUT4 translocation from the intracellular store to 
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plasma membrane in the skeletal muscles of the HFD animals. The finding is in 
conjunction to upstream insulin-induced Akt activation and increased glucose uptake in 




Figure 3.2.8 Distribution of GLUT4 protein and enzymatic activity of alkaline 
phosphodiesterase-1 in membranes of different sucrose gradient fractions. 
Membranes were prepared from skeletal muscles of fasted C57BL/6J mice, 30 min after 
administration with 0.5 unit/ kg insulin. Upper panel: 30 !g of protein from each fraction 
and the total membrane were subjected to Western blotting. Lower panel: Specific 
activity of alkaline phosphodiesterase-1 in each membrane fraction. The vertical bars 




Figure 3.2.9 Effects of DAA-1 and Ang-IV on insulin-induced GLUT4 translocation 
in skeletal muscle of C57BL/6J mice fed on HFD at the end of 52 weeks. Animals 
were fasted for 16 hours (overnight) and intraperitoneally administered with either insulin 
solution (0.5 U/ kg) or equivalent volume of PBS.  Animals were sacrificed by cervical 
dislocation 30 minutes later. The hind limb muscles were excised and its plasma 
membranes isolated by sucrose gradient. 10 !g of protein from the 25 % fraction of a 
discontinued sucrose gradient, and 30 !g of protein the total membrane (crude membrane) 
were subjected to SDS-PAGE. Upper panel shows representative data of GLUT4 protein 
from plasma membrane (PM) and total membrane of insulin and non-insulin treated 
animals. Bottom panel: PM GLUT4 content expressed against the total GLUT4 content.  
The vertical bars represent the SEM of samples obtained from 3 individual animals, 
assigning a value of 100 % to the non-insulin treated ND control. *Significantly different 
from corresponding animals fed with ND. #Significantly different from corresponding 
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The hind limb skeletal muscles of the animals were sectioned in a cryostat and used for in 
situ detection of ROS. The protein expression levels of gp91 NADPH oxidase, JNK 
phosphorylation and Ang-II induced JAK-2/ IRS-1/ PI3K attachment to Ang-II receptor 
were also studied by Western blotting. The main events of oxidative stress and Ang-II 
signaling induced JNK activation were examined as depicted in Figure 3.3.1: 
 
1. Oxidative stress 
ROS level 
gp 91 NADPH oxidase protein expression level 
 
2. JNK activation 
 





Figure 3.3.1 Experimental outline for the study of the effects of chronic 
treatment of DAA-1 and Ang-IV on oxidative stress and Ang-II signaling 
induced JNK activation in the skeletal muscles of HFD animals. 1- ROS and gp 
91 NADPH oxidase protein expression level; 2- JNK activation; 3- JAK-2/ IRS-1/ 
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NADPH oxidase transfers electrons and couples them to oxygen molecule to generate 
superoxide. The superoxide oxide spontaneously forms hydrogen peroxide and undergoes 
further reactions to produce reactive oxygen species. The skeletal muscles from the 
animals that received HFD for 52 weeks had almost six-fold increase in tissue ROS 
compared to the ND animals as shown in Figure 3.3.2 (p< 0.05). HFD animals treated 
with DAA-1 and Ang-IV (starting from week 0 and 24) were found to have significantly 
lesser tissue ROS compared to the HFD control animals. Notably, muscles from the 
DAA-1 treated HFD animals from week 0 showed less than half of the ROS when 
compared with the HFD control animals. In contrast, HFD animals received DAA-1 
treatment after week 24 and Ang-IV treated HFD animals (starting from week 0 and 24) 
displayed lower tissue ROS when compared with the HFD diabetic animals, but higher 
when compared with the ND healthy animals (p< 0.05). 
 
As shown in Figure 3.3.3, similar trend was observed in gp91 NADPH oxidase 
expression present in the skeletal muscle of the test animals using western blot analysis. 
More than two-fold increase of gp91 protein expression was observed in the skeletal 
muscle tissues of HFD diabetic animals compared to the ND healthy animals (p< 0.05). 




Figure 3.3.2 Effects of DAA-1 and Ang-IV on ROS formation in skeletal muscle of 
C57BL/6J mice fed on HFD at the end of 52 weeks. In situ detection of ROS in skeletal 
muscle of the treated animals as previously described at the end of 52 weeks. Tissue ROS 
was detected with DHE (red fluorescence) in cryostat sections of skeletal muscle and the 
intensity was detected using Imaging software (Image Processor, New York University). 
Images show representative results from 6 animals per group. The vertical bars represent 
the SEM of samples obtained from 6 individual animals. *Significantly higher than ND. 
#Significantly lower than HFD control group. (p< 0.05, one way ANOVA, post hoc 




Figure 3.3.3 Effects of DAA-1 and Ang-IV on the expression of gp91 NADPH 
oxidase in skeletal muscle of C57BL/6J mice fed on HFD at the end of 52 weeks. 
Animals were fasted for 16 hours (overnight) and were sacrificed by cervical dislocation. 
The hind limb muscles were excised and 100 !g (gp91) and 30 !g (actin) of protein were 
subjected to SDS-PAGE. Upper panel shows representative data of gp91 protein and 
actin. Bottom panel: gp91 protein content expressed against the actin content. The 
vertical bars represent the SEM of samples obtained from 3 individual animals, assigning 
a value of 100 % to the ND control. *Significantly higher than ND. #Significantly lower 
than HFD control group. (p< 0.05, one way ANOVA, post hoc Fisher’s LSD).  
&
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JNK is a major stress-sensitive MAPK activated by ROS induction. The JNK pathway is 
known to be activated through phosphorylation in various tissues in diabetic conditions 
and interfere with insulin action. Its role as a mediator in the progression of T2DM is 
highlighted in Figure 1.4.  
 
In parallel to the levels of tissue ROS, the skeletal muscles of HFD animals showed 
almost four-fold increase in both basal and insulin-stimulated redox-sensitive JNK 
phosphorylation compared to the ND animals (p< 0.05). DAA-1 treated HFD animals 
(week 0 and week 24) had significant decreased basal and insulin-stimulated levels of 
JNK activation in the skeletal muscle compared to the HFD control. The muscles of Ang-
IV treated HFD animals (week 0 and week 24), albeit showing significant decreased level 
of JNK activation when compared when the untreated HFD control, had higher JNK 
activation when compared with ND control animals (p< 0.05). It was observed that the 
peptides treated animals, had significant increases in tissue JNK activation compared to 
the ND control upon insulin stimulation. There were no differences in the total JNK 




Figure 3.3.4 Effects of DAA-1 and Ang-IV on basal and insulin-stimulated level of 
phosphorylated JNK in skeletal muscle of C57BL/6J mice fed on HFD at the end of 
52 weeks. Animals were fasted for 16 hours (overnight) and intraperitoneally 
administered with either insulin solution (40 U/ kg) or equivalent volume of PBS.  
Animals were sacrificed by cervical dislocation 5 minutes later. The hind limb muscles 
were excised and 100 µg of protein lysate was then resolved through SDS-PAGE, and 
probed with pJNK antibody for Western Blot analysis. The blot was reprobed with JNK 
1/2 antibody to determine the total JNK. Upper panel shows representative data of pJNK 
and JNK 1/2. Bottom panel: pJNK content expressed against the total JNK content. The 
vertical bars represent the SEM of samples obtained from 3 individual animals, assigning 
a value of 100% to the non-insulin treated ND control. *Significantly higher than ND. 
#Significantly lower than HFD control group. (p< 0.05, one way ANOVA, post hoc 







As shown in Figure 3.4.1, 52 weeks of HFD induced approximately four-fold increase in 
the attachment of JAK-2 and IRS-1 to AT1 receptor in the skeletal muscles of the test 
animals. The increase was significantly reduced in the peptides treated animals. The 
tissues of the HFD animals that were treated with DAA-1 and Ang-IV (starting from 
week 0 and 24) showed significant reductions of sixty and thirty percent in JAK-2 and 
AT1 receptor association, respectively, when compared to the HFD control animals. 
However, when compared to the healthy ND animals, the tissue JAK-2/ AT1 association 
remained significantly higher in DAA-1 and Ang-IV treated HFD animals. Similarly, the 
IRS-1/ AT1 interaction was more reduced in the skeletal muscles of DAA-1 treated HFD 
animals (starting from week 0 and 24), compared to the Ang-IV treated HFD animals 
(starting from week 0 and 24). Interestingly, the tissues of DAA-1 but not Ang-IV treated 
HFD animals were found to have similar levels IRS-1/ AT1 interaction to that of the ND 
control animals. There were no differences in the PI3K and AT1 receptor interaction 
observed in the skeletal muscles among all groups.  
 
From the data, DAA-1 seems to attenuate the increased IRS-1 interaction with AT1 
receptor in the skeletal muscles of HFD animals. Ang-IV was shown to, in lesser extent, 









Figure 3.4.1 Effects of DAA-1 and Ang-IV on the coupling of JAK-2, IRS-1 and 
PI3K to the angiotensin AT1 receptor in skeletal muscle of C57BL/6J mice fed on 
HFD at the end of 52 weeks. Animals were fasted for 16 hours (overnight) and 
sacrificed by cervical dislocation. The hind limb muscles were excised AT1 receptor 
protein was immunoprecipitated (IP) from muscle supernatant with AT1 antibody 
overnight. The conjugate were then incubated with protein A-agarose beads. Isolated AT1 
receptor (1000µg) was then resolved through SDS-PAGE and immunoblotted (IB) with 
JAK-2, IRS-1, PI3K and AT1 antibodies for Western Blot analysis. Upper panel shows 
the representative data of JAK-2, IRS-1, PI3K and AT1. Bottom panel: JAK-2, IRS-1 and 
PI3K content expressed against the total AT1 content.  The vertical bars represent the 
SEM of samples obtained from 3 individual animals, assigning a value of 100 % to the 
non-insulin treated ND control. *Significantly different from corresponding animals fed 
with ND. #Significantly different from corresponding animals fed with HFD. (p< 0.05, 
one way ANOVA, Fisher’s LSD)  
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There were no interaction of IRAP and PI3K observed in both basal and insulin-
stimulated in the skeletal muscles of ND and HFD control animals as shown in Figure 
3.5.1. Interestingly, Ang-IV treated HFD animals (starting from week 0 and 24) showed 
insulin-stimulated IRAP and PI3K interaction in the tissue and the effect was observed in 
concurrent to insulin-stimulated tyrosine phosphorylation of IRAP. The IRAP/ PI3K 
interaction was confirmed by probing for IRAP proteins in PI3K conjugates.  
 
The data suggests that Ang-IV, but not DAA-1 induced insulin-stimulated IRAP and 





Figure 3.5.1 Effects of DAA-1 and Ang-IV on basal and insulin-stimulated IRAP-
PI3K interaction in skeletal muscle of C57BL/6J mice fed on HFD at the end of 52 
weeks. Animals were fasted for 16 hours (overnight) and intraperitoneally administered 
with either insulin solution (40 U/ kg) or equivalent volume of PBS.  Animals were 
sacrificed by cervical dislocation 5 minutes later. The hind limb muscles were excised. 
IRAP and PI3K proteins were immunoprecipitated (IP) from muscle supernatant with 
respective antibody overnight. The conjugate were then incubated with protein A-agarose 
beads. Isolated proteins (1000µg) were then resolved through SDS-PAGE, and 
immunoblotted (IB) with pTyr, PI3K and IRAP antibodies for Western Blot analysis. The 
blot shows the representative data obtained from 3 individual animals. Upper panel: 
Western blot of IRAP probed with (i) PI3K antibody (ii) pTyr antibody.  Lower panel: 





Figure 3.6.1 shows the 30 min serum glucose level of ND animals after 6 weeks of 
treatment with DAA-1 and Ang-IV in the presence of AT1 and AT4 receptor blockers. 
ND animals treated with DAA-1 and Ang-IV had significantly lower 30 min blood 
glucose in OGTT (14.3 ± 0.3 mM and 14.3 ± 0.7 mM), compared to the water-treated 
control animals (17.9 ± 1.1 mM). Concurrent treatments of losartan and divilinal Ang-IV 
were shown to selectively block off the hypoglycaemic effects of DAA-1and Ang-IV, 
respectively (16.3 ± 0.6 mM and 18.2 ± 0.9 mM). In addition, concurrent intraperitoneal 
injection of indomethacin attenuates the hypoglycaemic action of DAA-1. The 
intraperitoneal injection doses of losartan (50 nmole/ kg/ day), divilinal-Ang-IV (300 
nmole/ kg/ day) and indomethacin (50 nmole/ kg/ day) used was established in previous 
studies (unpublished findings) to have no effect on the serum glucose in OGTT. The 
control animals with administration of losartan and divilinal Ang-IV alone had 30 min 
blood glucose of 17.2 ± 1.1 mM and 17.3 ± 1.0 mM, respectively. Worth mentioning, 
losartan was shown in Figure 3.6.2 to dose dependently affect the hypoglycaemic action 
of DAA-1.  
 
The data suggests that DAA-I and Ang-IV induced hypoglycaemic actions via the 




Figure 3.6.1 Effects of AT1 and AT4 receptor blockers on hypoglycaemic actions of 
DAA-I and Ang-IV in C57BL/6J mice. Five to 6 weeks old male animals were treated 
with either DAA-1 (600 nmole/ kg/ day) or Ang-IV (400 nmole/ kg/ day) via oral gavage. 
The animals concurrently received either losartan (50 nmole/ kg/ day) or divilinal-Ang-
IV (300 nmole/ kg/ day) or indomethacin (50 nmole/ kg/ day) via intraperitoneal injection. 
Control animals from were similarly treated with water by oral gavage and PBS by 
intraperitoneal injection. OGTT was performed at the end of 6 weeks and the 30 min 
serum glucose was measured. The vertical bars represent the SEM of mean values 
obtained from 10 individual animals. *Significantly lower than the value of untreated 




Figure 3.6.2 Effect of losartan on the hypoglycemic action of DAA-I in C57BL/6J 
mice. Five to 6 weeks old male animals were treated with either DAA-1 (600 nmole/ kg/ 
day) via oral gavage. The animals concurrently received various doses of losartan (50 to 
625 nmole/ kg/ day) via intraperitoneal injection. Control animals from were similarly 
treated with water by oral gavage and PBS by intraperitoneal injection. OGTT was 
performed at the end of 6 weeks and the 30 min serum glucose was measured. The 
vertical bars represent the SEM of mean values obtained from 10 individual animals. 
*Significantly lower than the value of untreated animals. (p< 0.05, one way ANOVA, 
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Ang IV is metabolised to shorter peptide fragments by endopeptidases like Ang (4-8), 
Ang (5-8) and Ang (3-4). In a preliminary study, it was observed that, C57 BL/ 6J black 
mice died from severe hypoglycaemia after 5 days of daily oral administration of 400 
nmole/ kg Ang (3-4) (data not shown). Hence the experiment was repeated using a dose 
of 200 nmole/ kg/ day Ang (3-4) instead. Figure 3.7.1 shows the 30 min serum glucose 
level of ND animals after 1 week of treatment with the metabolites of Ang-IV. The data 
shows that oral administration of 400 nmole/ kg/ day Ang (4-8) and 200 nmole/ kg/ day 
Ang (3-4) had significant hypoglycaemic effect on ND C57 BL/ 6J black mice. Ang (5-8) 
had no effect on the blood glucose of the ND animals. In accordance to previous findings, 
Ang (3-4) was found to possess anti-ACE activity and shown to have significant 
antihypertensive effect in both animals and human test subjects (Vercruysse et al. 2008). 
It is likely that this angiotensin fragment attenuates the blood glucose level via its potent 
ACE inhibitor activity. 
 
Ang (4-8) and Ang (3-4) were found to induce hypoglycaemic action as early as 1 week, 
compared to 4-6 weeks in Ang-IV treated animals. The data indicate that the metabolites 




Figure 3.7.1 Effects the metabolites of Ang-IV on blood glucose of C57BL/ 6J mice. 
Five to 6 weeks old male animals were treated with various doses of either Ang (4-8), 
Ang (5-8) or Ang (3-4) peptides. Control animals from were similarly treated with water 
by oral gavage. OGTT was performed at the end of 6 weeks and the 30 min serum 
glucose was measured. The vertical bars represent the SEM of mean values obtained 
from 10 individual animals. *Significantly lower than the value of untreated animals. (p< 





As shown in Figure 3.8.1, addition of high glucose concentration of 33.3 and 100 mM 
induced a significant sixty percent reduction in pancreatic beta cell viability after 4 day 
incubation. Subsequently, the cells were cultured in a 96-well plate in the presence of 
additional 33.3 mM glucose, and in the absence and presence of various concentrations of 
DAA-1, Ang-IV, and losartan (10-16 M to 10-6 M).  In Figures 3.8.2 and 3.8.3, DAA-1, 
but not Ang-IV was shown to dose-dependently protect the islets cells from 
hyperglycaemic condition. Figure 3.8.4 showed that losartan, like Ang-IV, was not able 
to protect islets cells from hypoglycaemic condition. The experiment with DAA-1 was 
repeated in the presence of 10-8 M losartan, and Figure 3.8.5 showed that higher 
concentration of DAA-1 was required to achieve maximum protective action i.e. 10-8 M 
compared to 10-12 M. 
 
The data suggest that the protection against hyperglycaemic-induced cell death by DAA-
1 was mediated through AT1 receptor and its action was competitively inhibited by 
losartan. DAA-1, Ang-IV and losartan do not affect the basal viability and growth of the 




Figure 3.8.1 Effect of hyperglycaemia condition on the survival of pancreatic beta-
TC-6 cells. Beta-TC-6 cells were cultured in 96-well plate in the presence of various 
concentrations of glucose (5.5 to 100 mM) that were added to the DMEM culture 
medium. The basal glucose concentration in the DMEM culture medium was 25 mM. 
Their survival was determined by MTT assay after 4 days of incubation. The vertical bars 
represent the SEM of samples obtained from 6 individual experiments. #Significantly 





Figure 3.8.2 Effect of DAA-1 on the survival of pancreatic beta-TC-6 cells cultured 
in high glucose concentration. Beta-TC-6 cells were cultured in 96-well plate in the 
presence of additional 33.3 mM glucose, and in the absence and presence of various 
concentrations of DAA-1 (10-16 to 10-6 M). The basal glucose concentration in the 
DMEM culture medium was 25 mM. Their survival was determined by MTT assay after 
4 days of incubation. The vertical bars represent the SEM of samples obtained from 6 
individual experiments. #Significantly different from control. *Significantly different 







Figure 3.8.3 Effect of Ang-IV on the survival of pancreatic beta-TC-6 cells cultured 
in high glucose concentration. Beta-TC-6 cells were cultured in 96-well plate in the 
presence of additional 33.3 mM glucose, and in the absence and presence of various 
concentrations of Ang-IV (10-16 to 10-6 M). The basal glucose concentration in the 
DMEM culture medium was 25 mM. Their survival was determined by MTT assay after 
4 days of incubation. The vertical bars represent the SEM of samples obtained from 6 
individual experiments. #Significantly different from control. *Significantly different 





Figure 3.8.4 Effect of losartan on the survival of pancreatic beta-TC-6 cells cultured 
in high glucose concentration. Beta-TC-6 cells were cultured in 96-well plate in the 
presence of additional 33.3 mM glucose, and in the absence and presence of various 
concentrations of losartan (10-16 to 10-6 M). The basal glucose concentration in the 
DMEM culture medium was 25 mM. Their survival was determined by MTT assay after 
4 days of incubation. The vertical bars represent the SEM of samples obtained from 6 
individual experiments. #Significantly different from control. *Significantly different 







Figure 3.8.5 Effect of DAA-1 in the presence of losartan on the survival of 
pancreatic beta-TC-6 cells cultured in high glucose concentration. Beta-TC-6 cells 
were cultured in 96-well plate in the presence of additional 33.3 mM glucose and 10-8 M 
losartan, and in the absence and presence of various concentrations of DAA-1 (10-16 to 
10-6 M). The basal glucose concentration in the DMEM culture medium was 25 mM. 
Their survival was determined by MTT assay after 4 days of incubation. The vertical bars 
represent the SEM of samples obtained from 6 individual experiments. #Significantly 
different from control. *Significantly different from reading obtained in the absence of 




Figure 3.8.6 Effects of DAA-1, Ang-IV and losartan on the survival of pancreatic 
beta-TC-6 cells cultured in basal medium. Beta-TC-6 cells were cultured in 96-well 
plate in the presence in the absence and presence of various concentrations of DAA-1, 
Ang-IV and losartan (10-16 to 10-6 M). The basal glucose concentration in the DMEM 
culture medium was 25 mM. Their survival was determined by MTT assay after 4 days of 







In the present study, the effects of DAA-1 and Ang-IV on insulin sensitivity, insulin 
signalling, and tissue oxidative stress in HFD-induced obese diabetic mice are 
investigated. C57BL/ 6J black mice was chosen to be the animal model in this study as it 
was observed that this strain of animals were differentially sensitive to dietary 
manipulations and has been extensively used in diabetes studies (Surwit et al. 1995; 
Surwit et al. 1988). Fifty-two weeks of HFD induced increases in body weight, energy of 
food consumed, blood glucose, insulin and FFA levels and insulin sensitivity in these 
animals. Significant differences in these animal characteristics were detected after 4 
weeks of HFD feeding, which has also been reported in a similar study (Prada, et al. 
2005).   
 
Chronic daily oral treatment of 600 nmole/ kg DAA-1 and 400 nmole/ kg Ang-IV 
induced hypoglycaemic effects and improved insulin sensitivity in HFD animals without 
affecting their body weight and food intake. The effects were observed in HFD animals 
that received the angiotensin peptides treatment before and after the onset of diet-induced 
diabetes (starting from week 0 and 24, respectively). Notably, both angiotensin peptides 
are not insulin secretagogues and are found to exert hypoglycaemic action in HFD 
diabetic animals by attenuating insulin resistance, based on the insulin sensitivity index. 
A high FFA level in diabetes is known to activate serine/ threonine kinases and mediate 
insulin resistance (Gao et al 2004). Based on this premise, both DAA-1 and Ang-IV seem 
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to attenuate increased blood FFA level induced by HFD in the initial development of 
diabetes. However, FFA level is known to increase with ageing (Bonadonna, et al. 1994; 
Tucker and Turcotte 2002) and both peptides do not seem to attenuate the age-related 
change in metabolism of adipose tissue.  
 
At cellular level, HFD significantly impaired skeletal muscle insulin-stimulated (i) IR and 
IRS-1 tyrosine phosphorylation, (ii) IRS-1/ PI3K association, (iii) Akt activation and (iv) 
GLUT4 translocation. In addition, HFD increased the IR and IRS-1 serine 
phosphorylation, ROS formation and activated JNK pathway (Hirosumi et al. 2002; 
Hotamisligil et al. 1993; Paolisso et al. 1995b). These detrimental defects have been 
found in muscle tissue from diabetic patients and rodents. In addition, HFD significantly 
induced increased formation of AT1/ JAK-2/ IRS-1 complexes at basal level. The actions 
of DAA-1 and Ang-IV on these detrimental defects are summarised in Table 4.1. The 
molecular cross talk between the insulin and Ang-II signalling systems plays a 
pathogenic role in the association between diabetes and cardiovascular diseases. Firstly, 
the attachment of Ang-II to AT1 receptor stimulated JAK-2 activity, and induced binding 
with IRS-1, was demonstrated to selectively impair insulin activation of PI3K-Akt 
pathway (Eguchi et al. 1998; Ishida et al. 1995). Additionally, Ang-II induces ERK1/2 
and JNK activation via AT1 receptor activation of Gq protein. The activated kinases 
promote phosphorylation of IR and IRS-1 in serine residues, impairing the early signal 
transduction of insulin (de Carvalho-Filho et al 2007). The effect of insulin-stimulated 
IRS-1/ PI3K activity is shown to be inhibited by Ang-II in a dose dependent manner 
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(Velloso, et al. 1996). The early events of the Ang-II and insulin cross-talk is highlighted 
in Figure 4.1. 
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Table 4.1 Summary of various protein expressions in tissues of the test animals 
 
 
Data from various protein expressions in skeletal muscle tissues of animals fed with HFD 




Figure 4.1 The early events of the Ang-II and insulin signalling cross-talk. Upon 
binding to AT1 receptor, Ang-II promotes the tyrosine phosphorylation of JAK-2 and the 
recruitment of IRS-1 and PI3K proteins. The AT1 also induces the activation of ERK and 
JNK. Once activated these proteins induce the serine phosphorylation of the IR and its 
associated proteins IRS-1 and PI3K, thereby inhibiting insulin-induced activation of Akt 





DAA-1 treatment significantly restored insulin-stimulated tyrosine phosphorylation of IR 
and IRS-1, IRS-1 and PI3K association, Akt activation and GLUT4 translocation in the 
skeletal muscles of HFD animals. Conversely, IR and IRS-1 serine phosphorylation, ROS 
formation and JNK activation were significantly attenuated in HFD animals treated with 
DAA-1. In addition, DAA-1 is also demonstrated to inhibit HFD-induced JAK-2 and 
IRS-1 attachments to AT1 receptor. These data suggest that the molecular mechanism by 
which DAA-1 improves insulin sensitivity involves modulations in the activation of ERK 
and JAK-2 kinases via AT1 receptor and association of IRS-1 to AT1 receptor. As 
previously reported, DAA-1 has the same effect on the insulin-stimulated tyrosine 
phosphorylation IRS-1 and GLUT4 translocation in diabetic KKAy mice and GK rats.   
 
Earlier studies indicate that DAA-1 acts on AT1 receptor as an agonist and exerts actions 
opposing those of Ang-II and prostaglandins transducer its action (Min et al 2000; Sim et 
al 2005; Sim et al 2006; Chen and Sim 2004; Wen et al 2004). Similarly, the data from 
the study also support the earlier studies. The hypoglycaemic action of DAA-1 is blocked 
by concurrent treatment with losartan and indomethacin, which suggest that DAA-1 acts 
via AT1 receptor and prostaglandins transduce the response. DAA-1 is shown to induce 
prostaglandins E2 and I2 release in human umbilical vein endothelial and A549 human 
alveolar basal epithelial cells; the release of the prostaglandins was similarly blocked in 
the presence of losartan and indomethacin in vitro (unpublished finding). The reduction 
in ROS formation found in DAA-1 treated HFD animals could be due to the actions of 
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the prostaglandins release. Prostaglandins are ligands to PPAR" and its actions include 
potentiation of insulin action and attenuation in inflammatory cytokines and ROS 
formation (Bishop-Bailey 2000; Leighton et al. 1990; Paolisso, et al. 1995a; Wasner, et al. 
1994). Cyclooxygenase-2 (COX-2) mediated inflammation and oxidative stress via 
prostaglandin F2 alpha was found to associate with T2DM in elderly population 
(Helmersson, et al. 2004). In addition, high glucose was found to increase expression of 
COX-2 and oxidative stress in mouse microvessel endothelial cells (Aljofan and Ding 
2010) and COX-2 inhibitor blocked expression of mediators of renal injury in a model of 
diabetes and hypertension (Cheng, et al. 2002). These evidences further support the 
involvement and importance of physiological equilibrium of prostaglandins in diabetes.  
 
In the present study, the onset of hypoglycaemic action of DAA-1 is 8 weeks after the 
onset of diet-induced diabetes (on week 32). The result is comparable to previous 
findings that a significant drop in blood glucose was observed in KKAy mice and GK 
rats after 4 and 6 weeks of daily treatment with DAA-1, respectively. Similar to that of 
thiazolidinediones anti-diabetic drug, the hypoglycaemic action of DAA-1 is possibly 
mediated by released prostaglandins acting on PPAR", which transcripts genes involved 
in glucose and lipid metabolism, requiring long onset of weeks to months. Nevertheless, 
the hypothesis of DAA-1 activating PPAR" via prostaglandins release remains to be 
clarified by signal transduction studies. Interestingly, similar long onset of action was 
observed in several hypoglycaemic compounds (Lo, et al. 2004; Miura, et al. 2002; 
Sugiura, et al. 2006).  
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Collectively, the present study shows that the mechanisms of hypoglycaemic action of 
DAA-1 involve three major pathways through AT1 receptor. Firstly, DAA-1 attenuates 
the deteriorating effects of Ang-II on insulin signalling cascade. DAA-1 acts on AT1 
receptors and impairs the docking of Ang II-activated docking of JAK-2 and IRS-1 
proteins to AT1 receptor. As a result, DAA-1 reduces JNK activation and serine 
phosphorylation of IR and IRS-1. Secondly, DAA-1 reduces the formation of ROS and 
expression level of gp91 protein of the NADPH oxidase, inevitably attenuates the insulin-
stimulated activation of IR and IRS-1 and its downstream signalling cascade, enhancing 
the translocation of GLUT4. Lastly, DAA-1 induces the release of prostaglandins which 
are important in glucose metabolism via to PPAR" activation, and as well as inhibiting 
the formation of ROS. The putative mechanism of hypoglycaemic action of DAA-1 is 






Figure 4.2 Putative mechanisms of hypoglycaemic action of DAA-1 involve three 
major pathways through AT1 receptor. 1- DAA-1 acts on AT1 receptors and impairs 
the docking of Ang II-activated docking of JAK-2 and IRS-1 proteins to AT1 receptor. As 
a result, DAA-1 reduces JNK activation and serine phosphorylation of IR and IRS-1. 2- 
DAA-1 reduces the formation of ROS and expression level of gp91 protein of the 
NADPH oxidase, inevitably attenuates the insulin-stimulated activation of IR and IRS-1 
and its downstream signalling cascade, enhancing the translocation of GLUT4. 3- DAA-1 
induces the release of prostaglandins which are important in glucose metabolism via to 




Ang-IV treatment enhanced insulin-stimulated Akt activation and GLUT4 translocation 
in the absence of significant improvement on insulin-stimulated IR and IRS-1 tyrosine 
phosphorylation and IRS-1/ PI3K association in the skeletal muscles of HFD animals. 
However, the inhibitory effect of Ang-IV on IR and IRS-1 serine phosphorylation, ROS 
formation and JNK activation were lesser compared to DAA-1. These findings suggest 
that Ang-IV improves insulin sensitivity by targeting components beyond the 
conventional insulin signalling pathway. Ang-IV is also demonstrated to inhibit HFD-
induced JAK-2 and IRS-1 attachments to AT1 receptor to a lesser extent compared to 
DAA-1. The data suggest that Ang-IV has certain influences on AT1 receptors. There are 
already numerous evidences showing Ang-IV has dual distinct actions on both AT1 and 
AT2 receptors. In the control of kidney blood flow, higher doses of Ang-IV were showed 
to mediate decrease in renal blood flow through AT1 receptor (Handa 2006; Li et al. 
2006), and induced increase in renal blood flow through AT4 receptor at lower doses 
(Coleman et al. 1998; Hamilton et al. 2001). Furthermore, Ang IV is shown to be a full 
agonist to AT1 receptor in micromolar range and yet able to elicit physiological responses 
that are independent of AT1 receptors in nanomolar concentrations. In accordance, the 
present study show that the effect hypoglycaemic dose of Ang-IV is 400 nmole/ kg and is 
blocked by concurrent treatment with divilinal Ang-IV but not losartan, suggesting the 
hypoglycaemic effect is mediated by AT4 receptor. 
 
Hence, the effects of Ang-IV on IRAP, an angiotensin IV receptor in the skeletal muscles 
of HFD animals were examined. It is revealed that Ang-IV induces ex novo insulin-
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stimulated tyrosine phosphorylation of the receptor that accompanied by PI3K attachment. 
This finding suggests that Ang-IV acts via IRAP, which binds and stimulates PI3K as 
activator of Akt. This novel finding of IRAP triggered PI3K activation is supported by a 
previous study in endometrial carcinoma cells. In this study, the author demonstrated that 
overexpression of IRAP in A-MEC cells induced remarkably high level of PI3K protein 
and showed higher degree of Akt activation and glucose uptake by insulin stimulation 
(Shibata, et al. 2007). Similarly, Ang-IV was found to stimulate PI3K and induced Akt 
activation in lung endothelial cells (Li et al. 2002). Moreover, high level of protein-
protein interaction between IRAP and PI3K was detected in brain tissue homogenate 
(unpublished findings), where abundant cerebral IRAP protein is found (de Wied et al. 
1993; Engelmann et al. 1996). However, phosphoinositide-binding domains like PX, PH 
and FYVE domains were not found on IRAP (Zhang et al. 1999; Zhang et al. 1998). 
Although not confirmed and remains to be proven, it is likely that the binding of PI3K to 
IRAP is linked by an intermediate molecule that contains one of these domains. The 
insulin-stimulated binding of PI3K to IRAP via tyrosine phosphorylation by Ang-IV has 
several implications. Firstly, the activation of IRAP is likely to transduce an intracellular 
signal that activates PI3K and Akt leading to the translocation of GLUT4 to plasma 
membrane as shown in the western blot data. The IRAP activation of cell proliferation 
signalling molecules like PI3K, Erk-1/ 2 and Akt were reported in previous studies (Li et 
al. 2002) (Shibata et al. 2007). The process is likely to involve dimerisation of the 
receptor and mediate through tyrosine phosphorylation. Secondly, the hypoglycaemic 
action of Ang-IV may involve the attenuation of IRAP recycling. As previously 
mentioned, it was well described that IRAP co-translocates with GLUT4 to the cells 
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surface in response to insulin stimulation. Several reports suggested that tyrosine and 
serine amino acids near the dileucine motif of IRAP undergo phosphorylation by protein 
kinase C-zeta upon insulin stimulation, leading the motif modification (Chi and Lodish 
2000; Yeh et al. 2007). These changes in the dileucine motif disrupt its interaction with 
ACD, the dissociation of ACD was found to coincide with IRAP/ GLUT4 translocation 
to the plasma membrane. It is likely that with insulin-stimulated tyrosine phosphorylation 
of IRAP by Ang-IV may therefore interfere its recycling and leads to prolonged exposure 
of GLUT4 at the cell surface. The putative mechanism of hypoglycaemic action of Ang-




Figure 4.3 Putative mechanisms of hypoglycaemic action of Ang-IV. 1- The insulin-
stimulated binding of PI3K to IRAP via tyrosine phosphorylation by Ang-IV is likely to 
transduce an intracellular signal that activates PI3K and Akt leading to the translocation 
of GLUT4 to plasma membrane. The process is likely to involve dimerisation of the 
receptor and mediate through tyrosine phosphorylation. 2- The hypoglycaemic action of 
Ang-IV may also involve the attenuation of IRAP recycling. IRAP co-translocates with 
GLUT4 to the cells surface in response to insulin stimulation. The mechanism is likely to 
involve phosphorylation of tyrosine and serine amino acids near the dileucine motif of 
IRAP by protein kinase C-zeta upon insulin stimulation. These changes in the dileucine 
motif disrupt its interaction with ACD, the dissociation of ACD was found to coincide 
with IRAP/ GLUT4 translocation to the plasma membrane. It is likely that with insulin-
stimulated tyrosine phosphorylation of IRAP by Ang-IV may therefore interfere its 










In the previous diabetic animal study, the hypoglycaemic action of DAA-1 was found to 
be biphasic, where the blood glucose lowering action became less effective with 
increasing doses of DAA-1 (Sim et al. 2007). Similar dose-dependent biphasic trend was 
also observed in the anti-hypertrophy actions of DAA-1 and Ang-IV in ischemic 
reperfused rat heart (Sim and Min 1998). The response was found to involve 
indomethacin-sensitive AT1 receptor subtype. Furthermore, the phenomenon was also 
reported in a renal vasculature study. Intrarenal bolus injection of Ang-IV produced a 
dose-dependent biphasic vasoconstriction in rat kidney, which was distinctly different 
from the monophasic vasoconstriction response of Ang-II (Handa 2006).  In accordance 
with previous studies, the biphasic response was found to be mediated by AT1 receptors 
(Fitzgerald, et al. 1999; Li et al. 2006; van Rodijnen, et al. 2002).  
 
Although the exact mechanism of action is not known, it is postulated that the biphasic 
response involved receptor down regulation in the presence of high doses of DAA-1 or 
Ang-IV. Angiotensin receptors belong to a family of GPCRs.  The number of cell surface 
GPCRs is regulated by agonist concentration through receptor internalisation and 
desensitisation (Timmermans, et al. 1993). These include rapid internalisation of the cell 
surface receptors upon agonist stimulation and reduced synthesis and increased 
degradation under prolonged exposure to the agonist (Böhm, et al. 1997; Zhang, et al. 
1996). DAA-1 could possibly exert its hypoglycaemic action through the activation of 
prostaglandin-producing AT1 receptors. High concentrations and prolonged stimulation 
of DAA-1 may down-regulate these AT1 receptor subtype and limit its hypoglycaemic 
 143 
effect. Ang-IV may decrease the number of IRAP available in the cell surface in a similar 
fashion. Furthermore, excessive DAA-1 and Ang-IV at high dose may bind to classical 
AT1 receptor mediating the intracellular pathway of DAG/ IP3 signalling.  
 
The possibility of hypoglycaemic effect induced by shorter endogenous angiotensin 
peptides (Unger et al 1998) has been examined in the present study. Three major 
fragments of Ang IV were investigated. Largely regarded as inactive peptide, Ang (5-8) 
was found to have no effect on blood glucose of ND animals after daily oral dose of 400 
nmole/ kg for 6 weeks. However, oral administration of 400 nmole/ kg/ day Ang (4-8) 
and 200 nmole/ kg/ day Ang (3-4) had significant hypoglycaemic effect on ND C57 BL/ 
6J black mice. This finding coincides with other reports that indicate Ang (3-4) possesses 
anti-ACE activity (Vercruysse et al. 2008) and it is likely that it lowers blood glucose via 
reduction of endogenous Ang-II. In addition, the data also further strengthens the 
hypothesis of cross-talk between insulin and Ang-II signalling systems. Notably, Ang (4-
8) and Ang (3-4) were found to induce hypoglycaemic action as early as 1 week, 
compared to 4-6 weeks in Ang-IV treated animals. The data indicate that the metabolites 
of Ang-IV acts via different pathway, possibly through inhibition of ACE. Hence, the 
hypoglycaemic effect of Ang-IV is most likely induced by Ang-IV itself but not its 
metabolites.  
 
Transport of the angiotensin peptides across Caco-2 cells and metabolism during transit 
were investigated previously (Chua, et al. 2004). The results showed that both DAA-1 
and Ang-IV are stable to nonenzymatic hydrolysis and no prominent degradation by 
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intestinal peptidases could be detected when diffused across the Caco-2 monolayer. 
Moreover, it should be pointed out that the Michaelis-Menten constant for most enzymes 
is within micromolar range and the effective oral doses in nanomolar range of these 
peptides would have avoid the enzymatic degradation.   
 
The present study strongly suggests that the hypoglycaemic action of DAA-1 is brought 
about by its action on the AT1 receptor, and Ang-IV produces hypoglycaemic response 
via IRAP. These findings further support the notions that the hexapeptide is able to (i) 
elicit responses that are AT4 receptor-dependent in nanomolar range and (ii) modulate the 
translocation of GLUT4 through its action on IRAP (iii) the mechanism of action 
involves tyrosine phosphorylation of IRAP, increased IRAP-PI3K interaction and 
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Pancreas has shown to express localised RAS (Leung, et al. 1999) and the localised Ang-
II has direct effect on the beta cell function and as well as pancreatic blood flow 
(Carlsson, et al. 1998; Tahmasebi, et al. 1999). More importantly, it was shown that by 
blocking actions of localised RAS, there were improvements in the islet morphology and 
insulin secretion in ZDF diabetic rats (Tikellis, et al. 2004). Currently, there is no therapy 
that targets to improve the functionality of the pancreas in diabetes. On the basis that 
DAA-1 and Ang-IV have shown to attenuate the deleterious effects of Ang-II, it is 
compelling to study the effects of these peptides on the pancreatic beta cell viability 
under hyperglycaemic condition.  
 
This study demonstrated that DAA-1, but not Ang-IV completely attenuated the cell 
death of pancreas beta cell induced by hyperglycaemic condition. The attenuation was 
dose-dependent and the maximum effect was seen at a concentration of 10-12 M. In the 
presence of 10-8 M losartan, the AT1 antagonist competitively inhibited the actions of 
DAA-1, with increased concentration of DAA-1 of 10-8 M required to attain the 
maximum anti-cell death effect. Losartan alone was found to produce a lesser extent of 
protection to the beta cells against hyperglycaemic-induced cell death compared to DAA-
1. These findings suggest that the attenuation of hyperglycaemia-induced cell death is 
mediated by the AT1 receptor, which is coupled to the release of prostaglandins upon 
activation of indomethacin-sensitive AT1 receptors. In this respect, prostaglandin E2 has 
recently been shown to protect MIN6 mouse beta cell against apoptosis and the anti-
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apoptotic role of prostaglandin E2 in pancreatic beta cells was reported to be crucial in 
diabetes (Papadimitriou, et al. 2007). In the same study, both arachidonic acid, precursor 
of prostaglandins, and prostaglandin E2 were upregulated in pancreatic islets under 
hyperglycaemic conditions. These increases in prostanoid generation were thought to 
serve as a defence mechanism against enhanced apoptosis in diabetes conditions. It is 
highly probable that DAA-1 protect the beta cells against hyperglycaemic induced cell 
death in similar manner. Interestingly, DAA-1 did not affect the viability of the beta cells 
under normal conditions, suggesting that the protective function of DAA-1 via 
prostaglandins release occurs only under detrimental conditions. Heitmeier previously 
reported this phenomenon in 2004 that exogenous prostaglandin E2 had no direct effect 
on beta cells under normal conditions.  
 
Intrinsic angiotensin-generating system with localisation and high expression of 
angiotensinogen has been found in the pancreas of both experimental animals and human 
(Hojima, et al. 1977; Leung et al. 1999; Tahmasebi et al. 1999). In particular, Ang-II and 
its receptors subtypes AT1 and AT2 were found distributed throughout the exocrine and 
endocrine parts of pancreas, including the insulin-secreting beta islets (Leung, et al. 1997; 
Leung et al. 1998). Physiologically, local RAS in pancreas is known to possess 
vasoactive effects in which Ang-II is the regulator for pancreatic vasoconstriction 
(Carlsson et al. 1998). Local generation of Ang-II was shown to reduce islet insulin 
secretion upon glucose stimulation (Fliser, et al. 1997). Although the mechanism of 
action remains unknown, Ang-II receptors have been previously shown to increase 
prostaglandin release, which modulates the insulin secretion, and blockade of AT1 
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receptors improve the functionality of the islets (Carlsson et al. 1998; Kelly and 
Laychock 1981). Recently, it was shown that hyperglycaemic condition dose-
dependently increased the expression of AT1 receptors in INS-1E pancreatic beta cells, 
accompanied by increased oxidative stress and impaired glucose-stimulated insulin 
secretion (Leung and Leung 2008). In the same study, the deleterious effects were 
similarly blocked off by losartan. In accordance to the findings of the present study, this 
convergence of evidence suggests that hyperglycaemic-induced beta cell death may be 
mediated by AT1 receptor-dependent oxidative stress and DAA-1 can reduce the damage 
possibly through the attenuation of NADPH expression, as observed in the skeletal 
muscle tissue. The lack of influence of Ang-IV on the hyperglycaemic-induced cell death 
was expected, as there are currently no reports on the localisation of Ang-IV and its 
receptors and their physiological role in pancreas.  
 
Measurement of the insulin level in the media of the insulin-secreting beta cells will help 
to confirm the effects of DAA-1 and Ang-IV are not mediated by inhibition of insulin 
release. However, one of the curtailments to this study is the lack of resources to 




In summary, the study enhances our understanding to the pathogenesis of diet-induced 
diabetes. HFD animals suffered from impaired insulin-stimulated tyrosine 
phosphorylation of IR and IRS-1, IRS-1/ PI3K association, Akt activation and GLUT4 
translocation. 
 
In addition, the present study shows that DAA-I improves glucose tolerance in diet-
induced hyperglycaemic mice, and supports similar action seen in diabetic rats and mice. 
The improved glucose tolerance was brought about by its action on the angiotensin AT1 
receptor. The angiotensin AT1 receptors in these hyperglycaemic mice was involved in 
mediating chronic inflammatory processes that were also attenuated by DAA-I. The 
findings also show that DAA-I is effective when given before and after the onset of 
hyperglycaemia indicating that it could be an effective prophylactic glucose level-
lowering agent.   Similar findings were obtained with Ang-IV, albeit via a different 
pathway that involved tyrosine phosphorylation of IRAP, increased IRAP-PI3K 
interaction and increased Akt activation. The study also demonstrates for the first time 
the protective action of DAA-1 against beta cell death under in vitro hyperglycaemic 
conditions.  
 
It is difficult to identify a single molecular target responsible to the disease as it is 
implicated with cardiovascular and renal complications. In addition, it is still unclear as 
to whether diet-induced diabetes is a primary disease or an outcome of well-concealed 
diseases. Nevertheless, the findings in this study reveal novel potential drug targets for 
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the treatment of diabetes. DAA-I acts by modulating the phosphorylation and interaction 
of IRS-1 and kinases of the insulin pathway and basal association of IRS-1/JAK to AT1 
receptor. In contrast, Ang-IV improves insulin sensitivity by targeting components 
beyond the conventional insulin signalling pathway by enhancing insulin-induced 
tyrosine phosphorylation of the IRAP, and the phosphorylation was accompanied by 
PI3K attachment suggesting that Ang-IV acts via IRAP, which binds and stimulates PI3K 
leading to the activation of Akt and glucose uptake. 
 
Lastly, the mechanism of anti-inflammatory actions of DAA-1 and Ang-IV were 
examined and provide a good basis for further research in overlapping diseases related to 
diet-induced obesity. Furthermore, the protective action of DAA-1 against 
hyperglycaemic-induced pancreatic beta cell death requires further examination and the 
findings can potentially elucidate the functioning of local tissue RAS. In addition, the 
novel finding of ex novo insulin-stimulated tyrosine phosphorylation of the IRAP by 
Ang-IV also opens up new vista in intense research on the recycling model of IRAP-
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